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                                                    ABSTRACT 
 
Coronary artery disease is by far the single biggest killer in the UK. 
Atherosclerosis is the underlying cause of coronary artery disease. 
Hypercholesterolemia is one of the major risk factors in the aetiopathogenesis 
of atherosclerosis. 3-Hydroxy Methyl Glutaryl CoA reductase (HMG CoA) 
inhibitors, known as statins, reduce cholesterol levels and offer mortality and 
morbidity benefit for those with coronary artery disease.The cardiovascular 
benefits from statins tend to be significant even in individuals with normal 
cholesterol levels which suggests that there are non-lipid lowering benefits of 
statins termed “pleiotropic” effects.  
Statins attenuate infarct size expansion due to lethal reperfusion injury either 
prior to ischaemia or at the onset of reperfusion by activating the pro-survival, 
Reperfusion Injury Salvage Kinase (RISK) pathway. As the duration of 
treatment acutely at the onset of reperfusion is too short to make any impact on 
cholesterol levels, it was hypothesized that the protection observed is due to a 
pleiotropic effect of the statins. 
The mechanism by which statins activate the RISK pathway is not entirely clear. 
Thus experiments with Langendorf perfused isolated rat heart preparation were 
used to obtain insights into potential mechanisms for statin’s pleiotropic effects 
in the setting of ischaemia-reperfusion by using Atorvastatin. Infarct size 
analysis and Western blot analysis were performed to measure cellular injury 
and protein activation respectively. Atorvastatin was shown to produce a 
reduction in infarct size when administered acutely during reperfusion at a dose 
of 50 micromol/l. 
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Atorvatstatin has affinity to the glucocorticoid receptor at levels comparable to 
potent glucocorticoids.  Glucocorticoids have also been shown to activate pro 
survival kinases. It was thus hypothesized that the acute cardiovascular effects 
of Atorvastatin may also be mediated by the glucocorticoid receptor, and would 
be blocked in the presence of the glucocorticoid receptor antagonist, RU486. 
However studies undertaken demonstarted inconclusive results as RU486 was 
itself shown to be protective and it would appear that it worked by an alternative 
mechanism. 
Since it is known that pre-ischaemic delivery of Atorvastatin also activates 
adenosine, an agent known to be cardioprotective. It was hypothesized that 
Atorvastatin administered during reperfusion may also protect the heart by an 
adenosine-dependent mechanism. However, despite the infarct sparing action 
of preischaemic administration of Atorvastatin being confirmed to be dependent 
on adenosine binding to its receptor, the protection of Atorvastatin administered  
during reperfusion was shown to be independent of adenosine.  
Finally, the acute effects of statins are believed to be  due to their action on the 
HMG CoA reductase enzyme which results in a decrease in mevalonic acid and 
isoprenyl intermediates.The isoprenyl intermediates such as Rho A, are 
inhibitors of the various components of the RISK pathway. We were able to 
demonstrate for the first time that mevalonic acid abrogates the infarct size 
reduction of Atorvastatin administered during reperfusion. Western blot analysis 
did not reveal a significant reduction in active Rho A levels, however there was 
a trend towards a reduction and this reflected in the infarct size studies. 
Although not conclusive, these results would suggest that the acute 
cardiovascular effects of Atorvastatin, when given at reperfusion, were due to 
its pleiotropic effects on Rho A.  
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1.0 INTRODUCTION 
Cardiovascular disease accounts for about 35% of the deaths in UK and of 
these 50 % of the deaths are as a result of Coronary Artery Disease (CAD)1. 
CAD is the most common cause of death in the UK.1 It is also a significant 
cause of morbidity and a significant burden to the healthcare system. This has 
resulted in the drafting of the National Service Framework for Coronary Artery 
Disease in the UK and in significant research for various treatment modalities. 
CAD presents in various clinical settings including acute myocardial infarction, 
acute coronary syndromes and angina. Early reperfusion is the treatment of 
choice. However reperfusion strategies such as percutaneous intervention 
(PCI) and thrombolysis have a thirty day morbidity of 8.5% and 14 % 
respectively2. Part of the reason for this morbidity, despite successful 
reperfusion, is thought to be due to the existence of lethal ischaemia-
reperfusion injury. 
The existence of lethal reperfusion injury over and above the injury caused by 
ischaemia was first demonstrated in dogs by Jennings et al3. This has 
subsequently been investigated and potential mechanisms have been 
demonstrated by various groups such as Hearse et al4, Fox et.al5, Opie et.al6 
etc. However early controversy stemmed from the possibility that this extension 
of infarct in the reperfusion phase could be just a continuation of the necrotic 
process that commenced in ischaemia. This problem is compounded by the 
inability to accurately track the development of necrosis with time7. 
There is now convincing evidence to suggest that lethal reperfusion injury does 
exist, as interventions targeting the reperfusion phase alone have demonstrated 
a reduction in infarct size both in animals and in humans7-10
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these interventions activate the cell’s own protective mechanisms which usually 
involves a signal transduction cascade that ultimately inhibits apoptosis and 
necrosis11,12.  
The last few years have opened up exciting avenues of research and 
translational work to characterize various pharmacological agents which are 
able to harness these protective mechanisms. One of the pharmacological 
ways of harnessing these protective mechanisms has been via the use of the 3- 
Hydroxy 3-Methyl Glutaryl CoA reductase inhibitors (HMG CoA reductase) i.e., 
Statins. 
Since the 1990’s numerous clinical trials with statins have demonstrated that 
reduction in serum cholesterol, significantly and safely reduces the incidence of 
coronary heart disease in those individuals with and without clinically apparent 
coronary artery disease13. Statins reversibly inhibit HMG CoA reductase, which 
is the rate limiting enzyme in the cholesterol biosynthetic pathway. They also 
increase hepatic clearance of LDL cholesterol14. This combined effect has been 
shown to bring about a very effective reduction in serum cholesterol. 
However the benefits from statins appear to be greater than what might be 
expected from lipid lowering alone14. This would suggest that there are 
cholesterol independent or pleiotropic effects of these agents14. While 
numerous pleiotropic effects have been demonstrated it is still not clear as to 
which of these effects are responsible for the attenuation of lethal reperfusion 
injury in the acute setting. 
The aim of the studies outlined in this thesis is to analyse the mechanism and to 
better understand the cardioprotective effects of acute statin therapy. It is hoped 
that such research will add to the available pool of information which will 
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subsequently permit a more rational approach to the use of statins as an 
adjunct in the treatment of Coronary Artery disease. 
1.1 CORONARY ARTERY DISEASE 
Coronary artery disease is burgeoning into a medical and socio-economic 
problem. The amount spent on prescriptions for CAD alone is close to £1.3 
billion per annum in the UK. The number of cases of PCI is also rising by 5% 
per year and there has been a 33% rise in the number of CABG between 1993 
and 2006 in the UK1. Thus a concerted effort has come about to tackle this 
disease by seeking methods for both primary prevention and secondary 
prevention. A good understanding of the underlying patho-physiology of the 
disease process would open up avenues for potential therapeutic measures. 
This area thus provides a fertile ground for translational research. 
CAD is a disease spectrum with acute myocardial infarction representing the 
most severe form of ischaemic injury and angina representing the mildest form 
of ischaemia. Atherosclerosis is the most frequent underlying cause for 
coronary artery disease15. Atherosclerosis is a chronic immunoinflammatory, 
fibroproliferative disease of large and medium sized arteries fuelled by lipids15. 
Myocardial infarction is precipitated by atherosclerotic plaque rupture and 
endothelial erosion both of which expose the arterial wall to prothrombotic 
factors16. This results in sub-total or total occlusion of the artery and precipitates 
myocardial ischaemia (Figure1.01). 
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Figure1.01: Various potential mechanisms of atherosclerosis associated coronary artery 
disease. Plaque rupture is by far the commonest cause of Acute Coronary Syndromes. 
Adapted and modified from Naghavi et al17. 
Early experiments with coronary artery occlusion in anaesthetized dogs 
demonstrated the presence of a wave-front of myocardial necrosis spreading 
from the endocardium to the epicardium and this was shown to be dependent 
on the duration of ischaemia. Experiments in dogs have demonstrated that the 
myocardium tends to be reversibly damaged if the period of ischaemia is limited 
to 15-20 minutes. However if ischaemia persists, myocardial necrosis 
commences and infarction is complete in 3-6 hours18. Thus the window for 
effective myocardial salvage following an infarct is limited and crucial. It is clear 
that restoration of coronary blood flow to the ischaemic segment is essential as 
seen in various trials utilizing thrombolytic agents such as GUSTO and 
GISSI19,20. Percutaneous intervention (PCI) or Coronary Artery Bypass Grafting 
(CABG) maybe warranted in addition to thrombolysis or even as a primary 
modality of treatment.  
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1.1.1 CARDIOPROTECTION AND ISCHAEMIA -REPERFUSION 
Despite being essential to prevent further tissue damage, reperfusion strategies 
such as thrombolysis or PCI are however associated with some infarct 
extension and this is termed lethal reperfusion injury. The therapeutic window 
for protection from lethal reperfusion injury could occur during two distinct 
phases. These are (1) pre-ischaemic phase and (2) reperfusion phase. Pre-
ischaemic protective procedures have been associated with the phenomenon of 
preconditioning. Preconditioning is a very potent cardioprotective mechanism 
and was discovered over two decades ago. It describes the phenomenon 
whereby short-lived episodes of myocardial ischaemia and reperfusion, prior to 
the infarct-inducing episode result in a significant reduction of infarct size21. 
However the clinical potential of this mechanism remains largely unrealised due 
to the inability to predict the onset of the infarct-inducing episode. 
Importantly renewed interest in cardioprotection associated with reperfusion 
injury was noted when some aspects of classic preconditioning were shown to 
be dependent on events occurring during the first few minutes of 
reperfusion22,23. The phenomenon of postconditioning has also contributed to 
this renewed interest. The term postconditioning has been used to describe the 
events occurring at reperfusion whereby brief periods of ischaemia interrupting 
the initial period of reperfusion results in cardioprotection as seen by a 
reduction in infarct size23. Various ligands have subsequently been identified 
which bring about the same effect as mechanical postconditioning and these 
agents induce what is termed pharmacological postconditioning24. In various 
animal models and in a human atrial muscle model, postconditioning has been 
shown to be as effective as preconditioning25. 
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However despite a thorough understanding of the mechanisms of reperfusion 
injury, the knowledge of the exact mechanisms by which pharmacological 
agents intervene in the cascade of reperfusion injury is evolving.  
1.2 MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY 
In order to gain mechanistic insight into the role of pharmacological agents in 
the attenuation of lethal reperfusion injury we need to understand the cellular 
responses to ischaemia and reperfusion. While reperfusion is essential after 
ischaemia for tissue salvage, it has been noticed that cells which are non-
lethally injured during ischaemia can progress towards irreversible cell damage 
and cell death by either necrosis or apoptosis during early reperfusion7.  
Reperfusion can result in either a full recovery or precipitate cell death in those 
cells that are reversibly injured, depending on various factors including the use 
of cardiovascular protective agents26. 
In order to draw a clear line of distinction between myocardial ischaemic injury 
and lethal reperfusion-injury we need to dissect out the exact sequence of 
events in each phase. 
1.2.1 MYOCARDIAL ISCHAEMIC INJURY  
Myocardial ischaemic injury is defined as a state in which arterial blood flow to 
the myocardium is insufficient to prevent intracellular metabolism from shifting 
from aerobic respiration to anaerobic metabolism27. However the limited 
delivery of substrate and the accumulation of metabolites also results in 
depression in cellular function27. During the first few minutes of ischaemia there 
is a switch from aerobic metabolism to anaerobic glycolysis. After the first few 
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minutes the rate of anaerobic glycolysis also declines due to inactivation of 
glyceraldehyde phosphate dehydrogenase28. 
The demand of the ischaemic tissue for high energy phosphate far exceeds the 
capacity of the reserves and anaerobic glycolysis to provide energy and thus 
there is a reduction in the intracellular ATP pool. As a result of ATP loss K+ ions 
leak out of the myocytes in an effort to retain ionic equilibrium and this leak 
quickly reaches steady state. However reperfusion at this stage will reverse all 
these changes. 
 As a result of anaerobic metabolism the intracellular levels of lactate and 
metabolites of creatine kinase rise and cause an increase in intracellular 
osmolarity. This results in water being able to diffuse into the cell but this is 
partially offset by the exit of K+ to the extracellular space and thus the cells will 
not swell. However the cells still retain their structural integrity and reperfusion 
at this stage is still able to restore homeostasis26. 
If ischaemia persists for 30 to 40 minutes then the intracellular adenine 
nucleotide pool is completely depleted because the cell will utilize all available 
ATP. ATP is dephosphorylated to ADP and AMP, which in turn are quickly 
converted to hypoxanthine. As a result protons, phosphate and ammonium ions 
accumulate resulting in a rise in intra cellular osmolarity. Lactate and other 
metabolites accumulate and increase the osmolar load which potentiates 
diffusion of water into the cells. At this stage the cells still retain their structural 
integrity. However there exists some oedema under the sarcolemmal 
membrane26. 
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If ischaemia persists beyond 60 minutes the plasma membrane phospholipids 
are degraded and lipid peroxidation begins, resulting in loss of cell integrity, cell 
swelling and eventual cell death (Irreversible cell damage)26.(Fig1.02) 
 
Figure 1.02: The various events occurring during ischaemia result in osmotic swelling, 
protease activation and eventual sarcolemmal rupture and necrosis. Adapted from 
Ferdinandy et al29. 
1.2.2 ISCHAEMIA REPERFUSION INJURY 
Reperfusion injury denotes a causal event associated with reperfusion that  has 
not occurred during the preceding ischaemic period and can be entirely 
attenuated by interventions delivered at reperfusion7. Myocardial reperfusion 
injury results in four types of injury7,30: 
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(a) Myocardial stunning: This refers to mechanical dysfunction that persists 
after reperfusion despite restoration of normal or near normal coronary flow30-32. 
This phenomenon is usually responsive to inotropic support in the setting of 
acute myocardial infarction and the myocardium usually recovers7. However 
this phenomenon is important as a tool for risk stratification of patients with 
CAD. 
(b) Reperfusion arrhythmias: These rhythm disturbances are potentially lethal 
but there are effective treatment strategies available. Reperfusion arrhythmias 
are defined as disturbances of rhythm that arise as a consequence of a total or 
partial restoration of blood flow in tissue which has been previously globally or 
regionally ischaemic33. These can occur as a result of rapid recovery of action 
potential characteristics during reperfusion, inhomogeneity of injury resulting in 
differential return of excitability to tissue and thus supporting re-entry circuits or 
increased automaticity33. These reperfusion arrhythmias may also occur due to 
the presence of free radicals and calcium stress33. Increased automaticity 
results in accelerated idioventricular rhythm while re-entry circuits result in 
ventricular tachycardia and multiple premature ventricular complexes34. 
Accelerated idioventricular rhythm is the commonest reperfusion arrhythmia in 
patients undergoing primary PCI and is associated with extensive myocardial 
damage and delayed microvascular reperfusion34. However ventricular 
arrhythmias are also believed to be markers of successful reperfusion in 
patients with ST elevation myocardial infarction who have been treated with 
thrombolysis35.  
Postconditioning has been effective in abolishing reperfusion arrhythmias in a 
rat in vivo model of ischaemia-reperfusion and this is related to the opening of 
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the mitochondrial KATP channels but is not related to the survival kinases 
PI3Kinase/AKT36. Conventional anti-arrhythmics such as beta blockers and 
amiodarone are effective in suppressing these arrhythmias33. Erythropoietin 
(EPO) has been shown to abolish ventricular arrhythmias in an in vivo canine 
model when administered just before reperfusion and this is dependent on PI3 
Kinase37. EPO has been shown to abolish premature ventricular complexes and 
ventricular arrhythmias in murine cardiac myocytes by activation of nitric oxide 
synthase38. Ranolazine has also been shown to be an effective anti-arrhythmic 
in a rat in vivo model and this is believed to be due to its inhibition of the late 
Na+ current39. Thus effective treatment strategies exist to prevent and control 
these events. 
(c) No reflow phenomenon: Loss of microvascular integrity and myocardial 
oedema results in the absence of subendocardial perfusion despite the 
presence of normal epicardial flow. This is seen in approximately one third of 
the patients who have PCI following an acute MI and is defined as poor 
resolution of ST segment elevation and poor ‘myocardial blush’ on angiography 
despite complete recanalization of the infarct-related epicardial artery40,41. This 
phenomenon is important because it is associated with higher rates of left 
ventricular dysfunction and mortality; this being partly related to the 
phenomenon of lethal reperfusion injury which is discussed below. 
(d) Lethal Reperfusion Injury: This phenomenon is the focus of this thesis. It 
was first described by Jennings et al in 1960 where they observed cell swelling, 
myofibril contracture, sarcolemmal disruption and appearance of calcium 
phosphate crystals in the myocardium during reperfusion42. Lethal reperfusion 
injury is defined as the injury caused by restoration of blood flow following an 
episode of ischaemia which leads to the death of cardiac myocytes that were 
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viable at the onset of reperfusion7,30,43. This phenomenon is complex and 
involves both necrosis and apoptosis which are two distinct mechanisms of cell 
death. The various alterations associated with lethal reperfusion injury are 
discussed in the following sections. 
1.2.3 LETHAL REPERFUSION INJURY 
In order to understand the basis of various cardioprotective strategies a 
systematic understanding of the various phenomena associated with lethal 
reperfusion-injury is essential. I will first briefly discuss the main morphological 
mechanisms of cell death which are necrosis and apoptosis. Cell death is 
classified according to morphological appearance as apoptosis, necrosis, 
autophagy and mitosis associated cell death44. 
1.2.3.1 NECROSIS AND APOPTOSIS 
Necrosis: Cell necrosis is generally initiated by non cellular mechanisms such 
as ischaemia, trauma and thrombosis and results in irreversible cell death 
characterized by cell swelling, depletion of high energy stores and disruption of 
cellular membrane due to fluid and electrolyte imbalances45,46. Necrosis usually 
affects contiguous tract of cells and the release of cellular debris results in 
inflammation and collateral damage47. This process is usually preceded by a 
70-100% depletion in ATP levels48. 
Necrosis is associated with an uncontrolled influx of calcium resulting in 
mitochondrial calcium overload and ATP depletion49. This rapid influx of calcium 
also inhibits caspase and endonuclease, both of which are involved in 
apoptosis, and thus preferentially results in necrotic cell death (accidental 
uncontrolled cell death)47. However there now exists evidence to suggest that 
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necrosis is mediated by signal transduction systems and catabolic 
mechanisms50,51. This process of calcium influx is overcome by promoting 
mitochondrial calcium sequestration by the protein bcl252. These mechanisms 
are described below. 
(a) Default or Fortuitous Necrosis: Necrosis, as a default pathway for 
programmed cell death, was first confirmed in baby mice kidney epithelial cells. 
In this model, exposure to hypoxia both in the in vivo and in vitro setting (when 
apoptosis and autophagy were inhibited) resulted in necrotic cell death53. In the 
above model inhibition of apoptosis (and thus mitochondrial membrane 
permeability) by knock-out of the pro-apoptotic proteins Bax/Bad and inhibition 
of autophagy by transfection with constitutionally active Akt (protein kinase) 
resulted in necrotic cell death. ATP depletion itself favours the switch from 
apoptosis to necrosis as sufficient ATP is required for the activation of pro-
apoptotic caspases48. Nitric oxide can also switch the mode of cell death from 
apoptosis to necrosis by inhibition of caspases54. 
(b) Regulated Necrosis: Signal transduction has been seen to occur in mice 
fibrosarcoma cells wherein TNF-α receptor activation is associated with 
necrosis via activation of death domain51. This activation is associated with a 
burst of mitochondrial ROS and increased permeability of outer mitochondrial 
membrane and is mediated via RIP-1 kinase51,55. This mechanism is known as 
necroptosis56. 
(c) Programmed Necrosis: Calcium overload and ROS activate cyclophylin D 
which is associated with the formation of the mitochondrial transition pore and 
this results in uncoupling of oxidative metabolism and mitochondrial swelling 
and disruption eventually leading to necrotic cell death57. 
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Necrosis can also be triggered by non-caspase proteases. Calcium overload 
can trigger the release of proteases such as calpains which act by cleaving 
proteins in the cytoskeleton and the release of lysosomal enzymes called 
cathepsins58,59. ROS release results in increased lysosomal membrane 
permeability and the release of lysosomal enzymes such as cathepsin B & D 
which eventually results in necrotic cell death60.  
High levels of reactive oxygen species (ROS) will result in ATP depletion and 
disruption of intracellular calcium homeostasis and cell death by necrosis49. The 
high levels of ROS also inhibits the apoptotic pathway by direct inhibition of 
caspases and DNA fragmentation61. 
These various mechanisms are represented in figure 1.03. 
 
 
Figure 1.03: Various Mechanisms of Necrosis. 
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Apoptosis: The term apoptosis was first coined by Kerr et al. to describe a 
pattern of morphological alterations associated with normal programmed cell 
death and certain pathological processes in vivo62. The changes they described 
include cell shrinkage, loss of contact with neighbouring cells, formation of 
cytoplasmic vacuoles, plasma and nuclear membrane blebbing and chromatin 
condensation.  
Apoptosis involves scattered cells within tissues and these are removed by 
macrophages or adjacent phagocytic cells before the loss of plasma membrane 
integrity63. It is not associated with inflammatory phenomenon64. The 
differences between necrosis and apoptosis are represented in figures 1.04 and 
1.05. 
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Figure 1.04: Necrosis is characterized by cell swelling, plasma membrane blebbing and 
cell lysis while apoptosis is characterized by cell shrinkage and phagocytosis. Adapted 
from Kerr et al62. 
APOPTOSIS NECROSIS 
(a) Active Process Passive Process 
(b) Cell Shrinkage Cell Swelling 
(c) Intact Membrane Membrane Rupture 
(d) No inflammation Inflammation 
(e) Evolutionarily Conserved 
pathway. 
Toxicant specific biochemical 
Mechanism. 
Figure 1.05: Morphological and functional distinction between Apoptosis and necrosis. 
Adapted from McConkey et al47. 
Apoptotic cell death is initiated by the activation of cell surface receptors 
(extrinsic pathway) or changes in mitochondrial permeability (intrinsic 
pathway)65. The extrinsic pathway involves the direct interaction of polypeptide 
homologues to the receptor to tumour necrosis factor and CD95/Fas which 
interact with the ‘death pathways’ via caspases66. The intrinsic pathway 
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mechanism involves indirect activation of caspases by agents that induce DNA 
damage such as irradiation and cancer chemotherapeutic drugs and 
pharmacological agents such as staurosporin67. Other stimuli that trigger the 
intrinsic pathway include loss of survival or trophic factors, toxins, hypoxia, 
oxidative stress and ischaemia-reperfusion 68. 
These apoptotic triggers result in a drop in the mitochondrial transmembrane 
potential and outer mitochondrial membrane permeability. This increase in 
permeability results in a release of apoptotic factors such as cytochrome C, 
Smac/DIABLO (another caspase activator) and apoptosis inducing factor into 
the cytosol69-71. Smac results in cytochrome C dependent caspase activation57. 
DIABLO binds to Inhibitor of Apoptosis proteins (IAP) and thus indirectly 
activates the caspases71. Apoptosis inducing factor mediates apoptosis by both 
caspase dependent and caspase independent actions70. Cytochrome C binds to 
Apoptosis protease- activating factor-1 which then interacts with caspase 9 and 
ATP to form the apoptosome47,72. This subsequently triggers caspase 3 and 7 
which eventually results in cell death. This has been schematically represented 
in figure 1.06. 
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Figure 1.06: Mechanisms of Apoptosis: (a) The extrinsic pathway is mediated by binding 
of peptides like Fas/CD95 and Tumour Necrosis Factor-α (TNF-α) to the CD95 receptor 
and TNF receptor (TNFR) respectively. These then bind to caspase 8 which subsequently 
activates caspase 3/7. (b) The intrinsic pathway is triggered by hypoxia, ischaemia-
reperfusion and irradiation and results in excessive outer mitochondrial membrane 
permeability and the release of Cytochrome C, SMAC/DIABLO and Apoptosis Inducing 
Factor into the cytosol. Cytochrome C binds to Apoptosis Protease Activating Factor 
(APAF) which then binds to caspase 9 and eventually activates caspase 3/7. 
SMAC/DIABLO bind to Inhibitors of Apoptosis Proteins (IAPS) and thus indirectly 
activates APAF/Cytochrome C/caspase 9. Adapted from www.apoptosisworld.com.377 
The Outer Mitochondrial Membrane permeability is controlled by the Bcl2 group 
of proteins73. The anti-apoptotic members Bcl2 and Bcl XL inhibit the release of 
apoptotic factors and are usually membrane bound while the pro-apoptotic 
members such as Bax, Bak, Bad and Bid are present in the cytosol and 
translocate to the outer mitochondrial membrane, where they promote the 
release of these factors72,74. Bid is cleaved by caspase 8 and binds to Bax or 
  Extrinsic Pathway    Intrinsic Pathway 
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Bak and ensures translocation of these on to the outer mitochondrial 
membrane, where they homo-oligomerize to form channels that are permeable 
to the apoptotic factors75. Anti-apoptotic members such as Bcl-2 bind to Bak or 
Bax and prevent the conformational change and thus the formation of ion 
channels76. Bad protein inhibits this action by binding to the Bcl2 protein and 
thus triggers apoptosis72. 
The other mechanism of outer mitochondrial membrane permeability is the 
mitochondrial permeability transition pore (MPTP) and this is discussed in a 
subsequent section. The MPTP is not triggered by the Bax/Bak system and can 
be modulated by the Bcl-2 pro survival proteins and depending on the degree of 
ATP depletion is associated with either necrosis or apoptosis73. These two 
mechanisms are illustrated in figure 1.07. 
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Fig 1.07: Outer Mitochondrial Membrane Permeability: (a) The induction of Bax/Bak 
results in increased outer membrane permeability to cytochrome c which results in 
caspase activation and cell death by apoptosis. The blue dots represent cytochrome c 
and apotogenic factors and the channel in the outer mitochondrial membrane consists of 
oligomerized Bax proteins. (b) The formation of the mitochondrial permeability transition 
pore results in mitochondrial swelling. Depending on the degree of ATP depletion, the 
cells progress to a caspase independent necrotic cell death or a caspase dependent 
apoptotic cell death. Taken from Martinou et al.73 
CONTRIBUTION OF APOPTOSIS AND NECROSIS TO LETHAL 
REPERFUSION INJURY IN THE CARDIOMYOCYTES 
While there is a lot of controversy regarding the percentage contribution of the 
two modes of cell death to reperfusion injury in the cardiomyocyte, it is 
becoming clear that both mechanisms are involved to varying extents68. 
Apoptosis has been shown to contribute to about 13% of cardiomyocyte loss in 
the setting of rat heart ischaemia-reperfusion injury77. Post mortem studies in 
patients with acute myocardial infarction treated with thrombolysis, has revealed 
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the presence of apoptosis in cardiomyocytes78. This has been also seen to 
occur in remote viable myocardium following acute myocardial infarction79. 
However these conclusions have been largely based on biochemical and 
immunohistochemical data. All morphological and ultrastructural data point 
towards necrosis as the predominant mode of death80. 
Mutant mouse models with mutations in various pro-apoptotic genes or ligands 
have shown a 50-60% reduction in myocardial infarct size. These mutations 
include mutation of the Fas ligand of the death domain, knockout of pro-
apoptotic Bid and overexpression of antiapoptotic Bcl-281,82. 
It has thus been hypothesized that cells undergo apoptosis and necrotic cell 
death early during ischaemia and then demonstrate morphological 
characteristics of necrosis once irreversibly injured68. The other postulate is that 
cardiomyocytes undergo a hybrid form of cell death involving characteristics of 
both apoptosis and necrosis68. The experiments in this thesis deal with 
infarction as a manifestation of necrosis. 
1.2.3.2 VASCULAR ENDOTHELIUM AND LETHAL REPERFUSION INJURY 
Lethal reperfusion-injury occurs due to changes in both the vascular endothelial 
cells and also the cardiac myocytes. However this thesis will primarily 
concentrate on the cardiac myocytes but I will briefly summarize the effect of 
reperfusion on the vascular endothelium. 
Microvascular dysfunction is an early and rate determining factor in the 
pathogenesis of ischaemia-reperfusion injury83. This is manifest as impaired 
endothelium dependent dilation in the arterioles, enhanced fluid filtration and 
leukocyte plugging in the capillaries and the trafficking of leukocytes and 
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plasma protein extravasation in the post capillary venules83. The endothelial 
cells are very sensitive to ischaemia and endothelium dependent dilation is 
affected significantly during the first few minutes of reperfusion84.  
Endothelium associated dilation is dependent on nitric oxide synthase (NOS) 
which produces a potent vasodilator, nitric oxide (NO). Reperfusion results in 
the production of free radicals such as superoxide which can interact with NO to 
form peroxynitrite free radicals and thus reduce the bioavailability of nitric oxide 
and also result in endothelial damage85. In a porcine model, it has been shown 
that addition of tetrahydrobiopterin (a cofactor of NOS) following ischaemia 
restores the availability of nitric oxide86. L-arginine is an essential substrate for 
nitric oxide synthesis and in a feline model, addition of L-arginine has shown to 
preserve endothelial function87. Reperfusion associated endothelial dysfunction 
is partly due to the upregulation of arginase (which results in the reduced 
bioavailability of arginine) by Tumour Necrosis Factor-α (TNF-α) as 
demonstrated in a mouse in-vivo model of ischaemia-reperfusion88.  
Endothelial and parenchymatous oedema along with the adhesion of 
neutrophils and platelets to the endothelial surface is responsible for the ‘no 
reflow’ phenomenon at the capillary level89. Reperfusion activates the 
complement system and the C5b-9 complement complex directly inhibits 
endothelium-dependent vasodilation while C5a activates inflammatory 
mediators such as Interleulkin-6 (IL6) and TNFα. C3b directly activates the 
binding of neutrophils to endothelium89. These are the main events that are 
responsible for ‘no reflow’ at the capillary level. 
The inflammatory response is responsible for injury that occurs at the post-
capillary level. Chemotactic agents such as IL-6, TNFα, Platelet Activating 
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Factor (PAF) etc., promote the adhesion between neutrophils and the 
endothelium and subsequent migration of neutrophils to the parenchyma 
resulting in neutrophil degranulation and production of Reactive Oxygen 
Species (ROS) and thus endothelial and myocyte cell death89. 
TNFα also triggers endothelial apoptosis via activation of caspases and this in 
turn influences apoptosis in the adjacent parenchyma90,91. Thus it is evident that 
endothelial cells have a role to play in the pathogenesis of reperfusion injury. 
1.2.3.3. EVENTS IN THE CARDIOMYOCYTE 
Lethal reperfusion-injury predominantly occurs within the first few minutes of the 
onset of reperfusion and is thought to be mediated by mitochondrial related 
mechanisms92. In addition, a delayed reperfusion injury is also thought to occur 
in vivo, which is mediated by polymorphonuclear cells that infiltrate the infarcted 
territory after 24 hours and result in apoptotic cell death7. 
It has also been shown that various measures to attenuate infarct extension as 
a result of reperfusion injury are most effective in early reperfusion. The 
following changes occur in the cardiomyocyte during the first few minutes of 
reperfusion and the mechanisms targeting these phenomena can result in 
cardioprotection: 
(a)Oxygen and calcium Paradox: During ischaemia the Na+/K+ ATPase on the 
sarcolemmal membrane and the Ca2+ ATPase in the sarcoplasmic reticulum 
become inactive as the energy stores are depleted. This results in accumulation 
of sodium and calcium in the cytoplasm. However during ischaemia the 
Na+/Ca2+ exchanger which is energy independent is active in its attempt to rid 
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the cell of excess sodium and results in worsening of the intracellular calcium 
concentration. 
However during the process of reperfusion, the return of oxygen results in re-
energisation of energy dependent Na+/K+ ATPase and Ca2+ ATPase pumps. 
This paradoxically worsens the intracellular calcium levels (discussed below) 
that results in hypercontarcture and cytoskeletal disruption and cell death. This 
is termed the ‘oxygen paradox’. Those cells that have irreversible damage to 
these channels during ischaemia are unable to correct the cation imbalance 
and thus progress to cell death without being affected by reperfusion injury.  
The cardiomyocytes that have functional sarcolemmal Na+/K+ ATPase and SR 
Ca2+ ATPase respond to re-energisation. Restoration of Na+/K+ ATPase activity 
results in a trans-sarcolemmal sodium gradient that is sufficient to activate the 
Na+/Ca2+ exchanger in the ‘forward mode’ i.e., extruding calcium for sodium. 
The Ca2+ ATPase activation results in accumulation of calcium within the 
sarcoplasmic reticulum leading to oscillatory calcium movement between the 
SR and the cytoplasm until the excessive calcium has been extruded from the 
cytoplasm. However the high levels of calcium that have accumulated within the 
myocyte during ischaemia and subsequently due to the oscillatory activity 
achieved during reperfusion, results in myofibrillar hypercontracture with the 
restoration of energy. This results in brittle cytoskeletal architecture which in 
turn compromises the cellular integrity7,93. These phenomena are illustrated in 
Figure1.08. 
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Figure 1.08: Reoxygenation results in activation of the Na/K ATPase (1) which in turn 
results in activation of the Na+/Ca2+ exchanger (2). This results in activation of the SR 
Ca2+ ATPase (3) which eventually contributes to oscillatory calcium levels (4) and thus 
myofibrillar contracture. Taken from Piper et al7. 
(b) pH Paradox:  Ischaemia triggers anaerobic glycolysis which in turn results 
in a depletion of ATP. This results in profound intracellular acidosis. However 
during reperfusion there is rapid normalization of the extracellular pH and this 
creates a H+ gradient. Furthermore reenergisation activates the H+ extruding 
mechanisms at the level of the sarcolemmal membrane. These include the 
Na+/H+ exchanger and the Na+/HCO3- symporter. The intracellular acidosis 
during ischaemia actually inhibits the responsiveness of the myofibrillar 
machinery to calcium.  
The correction of acidosis during reperfusion essentially reverses this inhibitory 
action and a responsive myofibrillar machinery in the presence of a calcium 
load, results in hypercontarcture. Of further importance is the fact that the 
accumulation of intracellular Na+, due to activation of the H+ extruding 
mechanisms, results in a reverse mode switch of the Na+/Ca2+ exchanger and 
thus increases the levels of intracellular calcium. This results in excessive 
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calcium load and hypercontracture7,93. These have been elucidated in 
Figure1.09. 
 
Figure 1.09: During ischaemia intracellular acidosis results in inhibition of myofibrillar 
machinery. Correction of extracellular acidosis during reperfusion, triggers the extrusion 
of H+ and thus sets in motion myofibrillar contracture in the presence of excess calcium. 
Taken from Piper et al7.  
(c) Increase in Osmolarity: The other crucial change that results in cell death 
is the increase in tissue osmolarity. During ischaemia there is an increase in the 
intracellular osmolarity due to accumulation of intracellular Na+. However the 
presence of hyperosmolar metabolites in the extracellular space inhibits any 
osmotic fluid overload within the cell and thus the cell does not swell up. The 
intracellular accumulation of Na+ occurs because of the inhibition of the Na+/K+ 
ATPase and also the activation of the Na+/H+ exchanger in an effort to maintain 
the intracellular pH during ischaemia. 
Reperfusion ensures a wash out of the osmotic metabolites in the extracellular 
space and results in an osmotic gradient that results in cellular and 
sarcolemmal swelling. However this in itself is not sufficient to cause cell 
rupture. Reoxygenation and the increased calcium load associated with 
reperfusion results in an increase in the structural fragility of the cell and thus 
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cell rupture occurs because of the associated oedema. It has also been 
demonstrated that there is the activation of proteolytic agents called calpains 
during reperfusion. These enzymes result in the proteolysis of ankyrin filaments 
that are responsible for the anchorage of the Na+/K+ ATPase to the 
sarcolemmal membrane. This worsens the intracellular Na+ load and thus 
further osmotic swelling occurs7,93. 
(d) Reactive Oxygen Species: Reperfusion also results in the formation of 
Reactive Oxygen Species (ROS). It was first demonstrated in perfused rat 
hearts that the use of free radical scavenger DMSO resulted in a reduction in 
CK release94. Experiments performed in rabbit hearts also showed that free 
radical production peaks at 15-20 seconds of reperfusion and this was 
associated with alterations in the recovery of high energy phosphate 
metabolism95. A ‘burst’ of H2O2 and hydroxyl radicals was seen to occur during 
the first 5 minutes of reperfusion and antioxidants were shown to improve cell 
viability in an isolated cardiomyocyte model96. Apart from antioxidants, 
ischaemic preconditioning and hypothermia have also been shown to inhibit this 
burst97. This ROS burst also triggers the induction of the mitochondrial 
permeability transition pore which in turn generates more ROS98. These 
detrimental ROS largely tend to be singlet oxygen species, superoxide or 
peroxynitrite. Peroxynitrite ROS results in lipid peroxidation and loss of cellular 
integrity7,93. 
Some ROS can also be beneficial in that they play a regulatory role in energy 
metabolism, apoptosis signalling, necrosis, ion channel regulation and vascular 
tone99. Experiments in rabbit hearts have shown that antioxidants abrogate the 
infarct reduction of ischaemic preconditioning thus suggesting a beneficial role 
for ROS in preconditioning100. Similar results have been obtained in 
 44 
cardiomyocytes101. The mitochondrial K+ ATP channels are central to this 
beneficial role in preconditioning102. However excessive amount of ROS is 
detrimental to cell survival. 
(e) Inflammation: Various inflammatory interactions that occur later as a result 
of neutrophil activation and accumulation contributes to reperfusion injury103,104. 
Neutrophil adhesion to the coronary vascular endothelium occurs within 
minutes of reperfusion and is associated with progressive endothelial 
dysfunction105. The neutrophils are present in the intravascular space for the 
first 6 hours of reperfusion and then migrate transendothelially into the 
parenchyma over the ensuing 24 hours and this is responsible for the delayed 
phase of reperfusion injury106. 
The triggers of neutrophil activation include cytokines such as tumour necrosis 
factor-α (TNFα), Interleukin6 (IL6), platelet activating factor and complement 
C5a which are released by the ischaemic perfused myocardium and regulated 
by the expression of NF-κB and ROS107,108. ROS such as the superoxide 
anions, hydroxyl radicals and hydrogen peroxide activate neutrophils by 
upregulating the adhesion molecules such as ICAM and p-selectin and also the 
activation of cytokines109,110. Lipid mediators like leukotriene B4, thromboxane 
A2 and Platelet Activating Factor are also involved in chemoattraction of 
neutrophils104. 
The binding of neutrophils to the endothelium is dependent on p-selectin. 
Subsequent rolling is dependent on β2 integrins such as CD11/CD18. The CD 
18 molecule binds to ICAM-1 adhesion molecule on the endothelium and 
subsequent neutrophil migration to the interstitium occurs as a result of binding 
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to PECAM. The neutrophils then bind to the myocyte via ICAM and releases 
proteases and cytotoxic oxidants104. 
Neutrophils play a role in cardiomyocyte death by one or many of the following 
mechanisms: (a) The release of ROS while interacting with the endothelium 
prior to transendothelial migration111. (b) release of proteases and collagenase. 
(c) microvascular embolization and endothelial dysfunction112. (d) Triggering 
apoptosis and infarct size extension in the late phase of reperfusion113. 
Various measures to reduce neutrophil associated reperfusion injury, have 
been used. Some of these include (a) Leukocyte depletion using neutrophil 
antiserum114. (b) Selective antibody therapy to adhesion molecules like anti- 
selectin antibodies115 and monoclonal antibodies to the integrins 
CD11/CD18116. (c) Adenosine which is known to have anti neutrophil activity by 
virtue of reducing superoxide formation117.This has been shown to be due to its 
activity on the A2A receptor118. (d) Local anaesthetics like lidocaine have an 
effect on infarct size by interacting with various mechanisms of neutrophil 
activation119. 
(f) The Mitochondrial Permeability Transition Pore (MPTP): The MPTP is a 
non specific pore that is present on the inner mitochondrial membrane which 
opens in response to the combination of calcium load, oxidative stress, pH 
change and ATP depletion associated with ischaemia-reperfusion injury. This 
uncouples oxidative phosphorylation and results in depletion of cellular ATP 
levels which in turn results in necrotic cell death120. The role of the pore in lethal 
reperfusion injury is discussed in the next section. 
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1.2.3.4. THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE 
The MPTP is a non specific pore that remains tightly closed under normal 
physiological conditions and is present on the inner mitochondrial membrane120. 
When open it is permeable to any molecule which is less than 1.5 kDa and 
usually results in hydrolysis of ATP and rapid depletion in energy stores121.  
It is not entirely clear as to what constitutes the pore though its 
electrophysiological and pharmacological characteristics have been determined 
by various experiments. It has been demonstrated in isolated rat heart 
mitochondria, that administration of cyclosporin A inhibits pore opening and that 
this is due to the inhibition of the activity of a matrix peptidyl-prolyl cis-trans 
isomerase known as cyclophilin D122. However it would appear that cyclophilin 
D aids in conformational change of an as yet unidentified protein under the 
influence of calcium120. 
The adenine nucleotide translocase (ANT) has also been shown to undergo 
conformational change and activate the MPTP in isolated rat heart and liver 
mitochondria122. ANT is activated by oxidative stress and inhibits the binding of 
adenine nucleotides to the cyclophilin D moiety in isolated rat heart 
mitochondria123. However experiments in mouse liver mitochondria have shown 
that genetic ablation of ANT has no effect on the ability for cyclosporin A to 
inhibit pore opening, although a higher concentration of calcium was required 
for the activation of the pore124.  
More recently a mitochondrial phosphate carrier has been implicated to be a 
component of the pore and its binding to cyclophilin D was shown to be 
inhibited by ubiquinone analogues (inhibitors of the pore), in rat heart 
mitochondria125. 
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MPTP opening results in neutralization of the mitochondrial transmembrane 
potential (ΔΨm) and inhibition of ATP synthesis92. This is associated with influx 
of water and mitochondrial swelling which results in the failure of the outer 
mitochondrial membrane and cell death. 
 
Fig 1.10: Components and formation of the MPTP and subsequent events. ANT: Adenine 
nucleotide translocase, PiC: Phosphate carrier, Cyp D: Cyclophylin D, CsA: Cyclosporin 
A and SfA: Sangliferin A. Taken from Javadov et al126. 
The pore can be inhibited by direct inhibitors such as cyclosporine, sangliferin A 
and ANT inhibitors such as bongkrekic acid127-129 and indirectly by ROS 
scavengers such as propofol, low pH inducers such as the Na+/H+ exchange 
inhibitor-cariporide, ubiquinone analogues and preconditioning/ 
postconditioning130-132. 
The pore remains shut during ischaemia but opens 2-3 minutes into reperfusion 
when the pH has normalised133. Further evidence that the pore is associated 
with reperfusion injury was obtained when sanglifehrin A and cyclosporine A 
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were shown to protect the heart from reperfusion injury127,134. MPTP opening is 
actvated by ROS, increased calcium which occurs due to inhibition of oxidative 
phosphorylation, the rapid correction of pH during reperfusion and ATP 
depletion30,92,130,135. This is represented in Figure 1.10. 
The various changes that occur with reperfusion injury can be altered by 
various direct and indirect mechanisms. The signal transduction mechanisms 
that can potentially attenuate reperfusion injury will be the subject of the next 
section.  
1.3 THE REPERFUSION INJURY SALVAGE KINASE (RISK) PATHWAY 
The Reperfusion Injury Salvage Kinases are a specific group of proteins that 
are activated in the reperfusion phase and confer cardioprotection by 
preventing lethal reperfusion injury30. These are the so called pro-survival anti- 
apoptotic kinases and include PI3K/Akt and ERK1/2136. There are various 
targets for these pro-survival kinases which have been elucidated by studying 
the effect of pharmacological manipulation of these kinases and this will be 
discussed in a separate section. The RISK pathway now also includes 
cardioprotective reperfusion salvage kinases such as Protien Kinase C-ε (PKC-
ε) isoform, Protein Kinase G (PKG), p70s6K and GSK 3β137. The RISK pathway 
and its effectors however represent a core component of a common 
cardioprotective pathway that terminates on the MPTP and unites 
preconditioning, postconditioning and pharmacological manipulation of 
reperfusion injury138. RISK pathway activation should occur in the first few 
minutes of reperfusion in order to be of any benefit. 
Necrosis and apoptosis contribute to myocardial reperfusion injury to different 
extents as already discussed45. However the contribution of necrosis to 
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reperfusion injury is significantly higher45. The prosurvival kinases that form part 
of the RISK pathway activate various downstream effectors that interact with 
both apoptotic cell death and necrotic cell death.  
1.3.1 COMPONENTS OF RISK PATHWAY AND ITS EFFECTORS 
1.3.1.1 PHOSPHATIDYLINOSITIDE-3-KINASE (PI-3K) 
The first link in the RISK pathway is the phosphatidylinositide-3-kinase (PI-3K). 
PI-3Ks are a family of evolutionary conserved lipid kinases that mediate many 
cellular responses in both physiological and pathological states139. PI3Ks are 
divided into three classes based on substrate specificity, mode of action and 
molecular structure. These are PI3K-1A, PI3K-1B, PI3K-2 and PI3K-3139. Class 
1 PI3Ks and class 3 PI3Ks are heterodimeric and consist of a catalytic and 
accessory subunit while class 2 PI3Ks are monomeric140. Class 1A kinases bind 
to the monomeric G protein ras and participate in phospholipid binding and 
protein-protein interaction while class 1B bind to G protein coupled receptors 
(GPCR)141. This eventually results in activation of tyrosine kinases and 
downstream effectors that mediate the various effects of PI3K. 
The molecular targets of PI3K are PDK-1 (Phosphoinositide Dependent Kinase-
1), Akt/PKB, GSK-3 β, mTOR, p70S6 kinase and Rho GTPases139. PDK-1 is an 
ubiquitously present 67 KDa kinase. PDK-1 is central in the PI3K signalling 
pathway and deletion of cardiac specific PDK-1 results in reduced cardiac size, 
cardiomyopathy and increased sensitivity to hypoxia142. PDK-1 phosphorylates 
other kinases like the AKT/PKB, Protein Kinase C (PKC) and p70S6 kinase143.  
 50 
PI3K mediated AKT/PKB and GSK 3β actions will be discussed in the next 
section. mTOR and p70S6 kinase are predominantly involved in cardiomyocyte 
growth.  
1.3.1.2 Akt/PKB 
Akt/PKB is a serine/threonine protein kinase and comprises of 3 closely related 
members which are Akt1, Akt2 and Akt3144. Akt appears to play an important 
role in majority of the cardioprotective actions145. PI3K activation results in the 
formation of phosphoinositol 3 phosphate (PIP3) which in turn brings about a 
translocation of Akt to the cell membrane. Akt is then activated by 
phosphorylation at threonine 308 site by PDK-1 and is regulated at the 
serine473 site by TORC2146,147. The targets of Akt include FOXO transcription 
factors, caspases, GSK-3β and the pro-apoptotic Bcl-2 family protein BAD65,136. 
PI3K activation enhances cell survival and antagonizes apoptosis by Akt/PKB 
activation148,149. 
The following mechanisms of Akt mediated cardioprotection are relevant in the 
setting of ischaemia-reperfusion injury: 
(a) Akt phosphorylates the pro apoptotic proteins BAX and BAD. This results in 
its inactivation and intracytoplasmic sequestration and prevents it from 
translocating on to the mitochondrial membrane, the action of which has been 
shown to inhibit the opening of MPTP136,150. Akt agonists have been shown to 
inhibit doxorubicin induced reduction in the anti- apoptotic protein Bcl XL in 
cardiomyocytes and this results in caspase 3 inactivation151. Preconditioning 
which triggers Akt activation has been shown to prevent ischaemia-reperfusion 
associated reduction in Bcl2 expression152,153. Akt inhibits caspase9 and 
caspase3 both of which are potent mediators of apoptosis153.  
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(b) Akt phosphorylation of GSK 3β (Glycogen Synthase Kinase-3β) at Serine 9 
results in the inactivation of this protein154. The exact downstream effector of 
GSK 3β is not entirely clear, however it has been shown that inactivation of 
GSK 3β results in delay of the opening of the MPTP155. Nishihara et al did 
demonstrate that phosphorylation of GSK 3β in response to preconditioning and 
erythropoietin treatment resulted in a decrease in the association of ANT and 
cyclophylin D and thus resulted in inhibition of pore opening156. It has also been 
suggested that it indirectly inhibits MPTP opening by reduction in the amount of 
reactive oxygen species (ROS) release and also its interaction with the PKC 
(Protein Kinase C) domain of the mitochondrial ATP dependent potassium 
channel (Mito-K-ATP)136,155,157. GSK 3β inhibition is also known to occur via 
actvation of p70s6k155.  PI3K also enhances glucose uptake by an Akt 
dependent translocation of the insulin dependent GLUT4 transporters to the 
plasma membrane and increases glycogen synthesis by Akt mediated GSK 
inhibition158,159. 
However it has recently been shown that mice hearts with GSK double knockin 
inhibition did not attenuate the ability to pre or post-condition these hearts160. It 
thus remains unclear as to whether phosphorylation of GSK 3β is involved in 
Akt dependent inhibition of pore opening. 
(c) Endothelial Nitric Oxide Synthase (eNOS) is another downstream effector of 
Akt. It may have the potential to inhibit MPTP opening either through its activity 
on PKG-PKCε-mito KATP channel161 or through the production of Nitric oxide 
which eventually activates PKG, an inhibitor of MPTP opening162. 
(d) Hexokinase-2 is expressed in cardiomyocytes and has been shown to be 
phosphorylated by Akt in neonatal rat ventricular myocytes163. The dissociation 
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of hexokinase-2 from the outer mitochondrial membrane has been associated 
with increased susceptibility of mitochondria to ROS induced activation of 
MPTP, in adult cardiac myocytes164. It is proposed that the preferential 
availability of ATP to hexokinase results in a constant supply of ADP to the 
mitochondria and this is responsible for its resistance to ROS induced depletion 
in ATP154. 
(e) Akt is also known to activate cGMP and PKG which phosphorylates 
phospholamban and thus has an effect on Ca2+ uptake of the sarcoplasmic 
reticulum. This is mediated via eNOS. This in turn has been shown to inhibit the 
MPTP opening136,165,166. 
1.3.1.3 EXTRACELLULAR SIGNAL REGULATED KINASE 1&2 (ERK1/2) 
ERK1 & 2 belong to the family of proteins called Mitogen Activated Protein 
Kinases (MAPKs)167. The MAPKs are a family of serine/threonine protein 
kinases whose function and regulation has been evolutionarily conserved168. 
MAPKs regulate a wide range of functions including cell growth and 
differentiation, gene expression, mitosis, cell motility, metabolism, cell survival 
and apoptosis and embryogenesis169. ERK1 &2 consists of a 42 and a 44 KDa 
kinase (p42 &p44)170. ERK1/2 are activated by the MAP kinase/ERK kinase 
(MEK1/2) which in turn are activated by small G proteins ras-raf167. Protien 
Kinase Cα (PKCα) has also been shown to phosphorylate raf and thus activate 
ERK1/2171. 
Various cardioprotective agents and mechanisms have been shown to activate 
ERK1/2. Postconditioning has been shown to activate ERK1/2 in isolated buffer 
perfused rabbit heart but not PI3K/Akt signalling172. Primary cardiac myocytes 
when exposed to urocortin have been shown to protect the cells from 
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reperfusion injury and this is associated with rapid phosphorylation of 
ERK1/2170. Urocortin is a peptide related to the hypothalamic corticotrophin- 
releasing hormone and binds with high affinity to the corticotrophin –releasing 
hormone receptor 2β which is present in the heart170. Administration of 
erythropoietin, both in vitro and in vivo rat heart models, has been shown to 
reduce infarct size and this paralleled the activation of ERK1/2173.  
ERK1/2 has been shown to inhibit apoptosis by inactivating the proapototic 
BAD and this is dependent on phosphorylation of p90rS6 kinase or p70S6 
kinase174,175. ERK1/2 also promote cell survival by phosphorylating and 
stabilizing the expression of the anti apoptotic protein Mcl1176. It also inhibits 
caspase 9 activity and thus regulates apoptosis177. 
The various mechanisms associated with RISK pathway activation have been 
illustrated in figure 1.11. 
 
Fig 1.11: Various mechanisms of RISK pathway mediated cell survival. Adapted from 
Hausenloy et al136. 
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Various pharmacological agents have been shown to activate the RISK 
pathway and this has opened up a plethora of potential cardioprotective agents 
that can be potentially used as adjuncts in reperfusion. 
1.3.2 MYOCARDIAL PROTECTION BY ADJUNCTS USED AT 
REPERFUSION 
A variety of adjuncts have been shown to protect the heart from reperfusion 
injury by recruiting the RISK pathway. The list of agents is constantly evolving 
but only a few of these have translated into viable agents in human trials. Some 
of these agents are discussed below. 
(a) Adenosine: Adenosinergic mechanisms have long been established as 
central to ischaemic preconditioning. However it is increasingly becoming clear 
that it is also central to postconditioning and pharmacological attenuation of 
reperfusion injury. Adenosine has 4 different receptor targets which are 
adenosine receptor isoforms: A1, A2A, A2B & A3. It has been shown in various 
studies that adenosine agonists when administered during reperfusion acts via 
the A1 and A2B receptors and activates the PI3 Kinase and MEK1/2 pathway to 
eventually activate the mito K+-ATP channels178,179. It has also been shown that 
activation of the A3 receptor results in infarct sparing through GSK3β and direct 
inhibition of MPTP166. Disappointingly the clinical trials utilizing adenosine in 
Acute Myocardial Infarction have not shown a similar infarct sparing effect180,181. 
This has been attributed to the fact that infarct size measurement mechanisms 
are not robust enough in clinical trials166. The role of adenosine in 
cardioprotection has been discussed in more detail in a separate section. 
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(b) Metformin: The results of UKPDS34182 trial suggested that Metformin 
offered benefits to diabetic patients who are overweight with ischaemic heart 
disease. In the UKPDS study 1704 patients were recruited and randomly 
assigned to conventional diet control, intensive therapy with sulphonylurea and 
insulin or Metformin alone. It was noted that the incidence of myocardial 
infarction was 36 % less in the Metformin group when compared to the 
conventional treatment group. However the glycaemic control was similar in 
both the treatment groups and this may suggest that Metformin has additional 
cardioprotective effects apart from its antihyperglycaemic actions.  
Metformin has been shown to improve cardiac function in streptozotocin 
diabetic rats in an isolated rat heart model183. It has been shown to reduce 
infarct size in isolated perfused rat hearts subjected to global ischaemia184. 
Further insight into the mechanism of action was obtained by experiments in the 
isolated rat heart model and in cardiac myocytes, wherein metformin 
administered at reperfusion was able to reduce infarct size in both diabetic and 
non-diabetic hearts and this was shown to be dependent on PI3k/AKT inhibition 
of MPTP opening185. 
In bovine aortic endothelial cells metformin has been shown to improve 
endothelial function by PI3K mediated activation of AMP activated protein 
kinase (AMPK)186. In the same study this was shown to be dependent on the 
phosphorylation of eNOS and increase in the bio-availability of nitric oxide. 
AMPK is a phylogenetically conserved heterotrimeric protein that is activated by 
pathological stresses such as glucose deprivation, hypoxia, oxidant stress and 
osmotic shock187. In a mouse in vivo model Metformin has been shown to 
reduce infarct size when administered prior to ischaemia and at the onset of 
reperfusion and this effect is dependent on activation of AMPK and eNOS188.  
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Recent data from a rat model of myocardial infarction (ex vivo and in vivo) has 
shown that acute cardiovascular protection of Metformin administered at 
reperfusion, was dependent on adenosine receptor stimulation probably via the 
increase in intracellular adenosine concentration189. This may be a potential 
explanation for AMPK associated activation of eNOS as AMPK increases the 
availability of AMP, the concentration of which is a critical determinant of the 
endogenous adenosine pool189. 
(c) Adipocytokines: Adipose tissue is now recognised to be an organ with 
endocrine activity. It has been shown to secrete numerous hormones that have 
been collectively termed adipocytokines. Leptin is an adipocytokine that was 
originally discovered to be associated with obesity and the metabolic syndrome. 
It has since been demonstrated in an ex vivo animal model to attenuate infarct 
size when administered during reperfusion. This is due to activation of the RISK 
pathway and inhibition of the opening of the MPTP190.  Apelin another 
adipocytokine has also been shown to be directly cardioprotective during 
reperfusion by activating the RISK pathway191. Similar acute cardioprotection 
has been demonstrated with adiponectin and visfatin192,193, suggesting a 
general protective effect of these agents that activate the RISK pathway.  
(d) Cyclosporin A: Cyclosporin A is an immunosuppressive drug which is 
thought to inhibit the opening of the MPTP by preventing the binding of 
cyclophylin D to ANT and this has been shown to occur at very low 
concentrations194. Cyclosporin A was first shown to be cardioprotective in an 
isolated rat heart model when administered prior to ischaemia128. This 
protection was manifest as an improvement in left ventricular developed 
pressure (LVDP) and also better ATP/ADP ratios128. Subesequently Hausenloy 
et al demonstrated in an isolated rat heart model that cyclosporin administered 
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at reperfusion reduced infarct size and that this was related to the inhibition of 
the MPTP195.  
In a small proof of concept clinical trial cyclosporin was administered to 58 
patients prior to PCI for an acute ST elevation myocardial infarction. Troponin I 
and CK levels were used as surrogate markers of myocardial injury and in one 
subgroup cardiac MRI was used to assess infarct size. The release of CK and 
the absolute mass of infarcted tissue (MRI assessment at day 5 post 
myocardial infarct) was significantly lower in the Cyclosporin group196. 
(e) Insulin: Insulin is one of the first pharmacological adjuncts that was shown 
to be cardioprotective when administered during reperfusion. It has been shown 
to be protective in animal studies and in clinical studies197,198. This has been 
demonstrated to involve the RISK pathway and the endothelial nitric oxide 
synthase and is believed to be predominantly an antiapoptotic effect199. 
However administration of High dose Glucose Insulin Potassium (GIK) in 
patients with ST Elevation Myocardial Infarction as part of the CREATE-ECLA 
trial did not shown any cardiovascular benefit. This study was carried out with 
7510 patients200. As a treatment agent its use is complicated by the risk of 
hypoglycaemic episodes. 
(f) Rho Kinase Inhibitors (Fasudil): Rho kinase is a G protein coupled kinase 
which is activated by the Rho A protein. Rho kinases are stimulated by hypoxia 
and vasopressors like angiotensin and are negative regulators of PI3 
kinase/Akt/eNOS pathway201,202. Rho kinase inhibition with administration of 
Fasudil at reperfusion has been shown to be cardioprotective in rat hearts and 
this protection was ameliorated by the administration of Akt and eNOS 
inhibitors203. The downstream targets of the Rho kinases still remains to be 
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elucidated, however it is speculated that this could be caspase3 mediated 
activity or Akt dependent maintenance of the balance between pro apoptotic 
and antiapoptotic mechanisms via Bcl2 regulation204,205. Rho kinases have been 
described in more detail in a separate section. 
(g) Erythropoietin: Erythropoietin (EPO) is a hormone that is produced in the 
juxtatubular cells of the kidneys and has a regulatory function with respect to 
erythropoiesis and is currently of therapeutic value in treating anaemia of 
chronic disease173. However in a rat in vivo model EPO has been shown to 
attenuate infarct size in the heart when administered prior to reperfusion and 
this was associated with reduced DNA fragmentation in rat cardiac myoblasts 
exposed to hypoxia and reoxygenation206. Administration of darbepoietinα (a 
long-acting analog of EPO) prior to ischaemia-reperfusion has been shown to 
protect via MAPK/mitochondrial K-ATP channel dependent mechanism in an in 
vivo rat heart model207. 
EPO has also been shown to protect cardiomyocytes from ischaemic injury and 
this is mediated by akt208. In a cardiomyocyte model EPO has been shown to 
be protective and this is related to upregulation of eNOS and NO209. EPO 
administered at reperfusion has also resulted in infarct size reduction in both 
isolated rat heart and an in vivo rat heart model and this has been shown to be 
dependent on PI3k and ERK173. Similarly EPO administered at reoxygenation 
has been shown to be protective in a human atrial trabecular model of hypoxia-
reoxygenation and this effect is dependent on PI3K/AKT and ERK1/2 activation 
and a reduction in caspase3 activation210. 
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(h) 3-Hydroxy-3- Methyl Glutaryl CoA reductase (HMG CoA) Inhibitors 
(Statins): Statins are a group of drugs that are involved in the inhibition of the 
cholesterol biosynthetic pathway14. They are used in the treatment of 
hyperlipidemia and also in primary and secondary prevention of Ischaemic 
Heart Disease211. Statins have also been shown to have a number of other 
actions not related to its cholesterol lowering activity and these have been 
collectively termed pleiotropic actions14. These pleiotropic actions are the 
subject of this thesis and a brief review of this will form the basis of the next 
chapter. 
1.4 STATINS, CHOLESTEROL AND CARDIOPROTECTION 
Elevated levels of plasma cholesterol have long been established as an 
independent risk factor for atherogenicity and thus ischaemic heart disease. 
This has been exemplified by the Framingham study and the Multiple Risk 
Factor Intervention Trial (MRFIT) study212. While dietary cholesterol can affect 
the serum cholesterol levels, hepatic biosynthesis is the major source of serum 
cholesterol.  
The rate limiting enzyme in the cholesterol biosynthetic pathway is the 3- 
Hydroxy 3-Methyl Glutaryl CoA reductase (HMG CoA reductase) and this 
enzyme catalyses the conversion of HMG CoA to mevalonic acid213. Mevalonic 
acid is a common precursor for both cholesterol biosynthesis and the synthesis 
of isoprenoids such as farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate. The isoprenoid geranylgeranyl pyrophosphate is required for 
activation of Rho group of proteins. This has been schematically represented in 
figure 1.12. 
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Figure1.12: Cholesterol and Isoprenoid synthetic pathway (Cardiomyocytes). Taken from 
Bonetti et al214. 
 
The first statin to be discovered was isolated from the fungus Penicillium 
citrinium and was called Mevastatin215. However this did not enter clinical use 
due to its hepatocellular toxicity. The first statin to gain approval for clinical use 
was lovastatin which was isolated from Aspregillus terreus216. Since then 
numerous statins both chemically modified and naturally occurring have been 
commercially availavable. These include Pravastatin, Simvastatin, Atorvastatin, 
Cerivastatin, Fluvastatin, Pitavastatin and Rosuvastatin14. Atorvastatin and 
Rosuvastatin are completely synthetic molecules217. The structure of some of 
the statins has been represented in figure 1.13. 
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Atorvastatin 
 
 
Simvastatin 
 
 
 
Pravastatin 
Fig1.13: Chemical structure of Statins: Atorvastatin and Simvastatin are lipophylic while 
Pravastatin is hydrophilic. Adapted from Pasha et al and van leuven et al217,218. 
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Statins, by virtue of binding to the active site of the HMG-CoA reductase 
prevent the substrate-product transition state of the enzyme and reduce the 
hepatic synthesis of cholesterol219. Statins also increase the expression of 
hepatic LDLc receptors and thus increase the serum clearance of cholesterol. 
Statins bind to the enzyme with an affinity in the nanomolar range and 
effectively displace the natural substrate of the enzyme that binds with an 
affinity in the micromolar range220. All statins differ in their potency. The newer 
statins such as Atorvastatin, Rosuvastatin, Pitavastatin, Fluvastatin and 
Cerivastatin are more potent at reducing cholesterol synthesis when compared 
to older statins such as Simvastatin, Pravastatin and Lovastatin221. Statins also 
differ in their lipophylicity and this may influence the ability of lipophilic statins 
such as Simvastatin and Atorvastatin to have extra-hepatic effects14. 
Pravastatin is more hydrophilic because of the hydroxyl moiety.  
Statins play a major role in primary and secondary prevention of ischeamic 
heart disease by virtue of reduction in the plasma cholesterol levels. This has 
been demonstrated by various trials such as the Scandinavian Simvastatin 
Survival Study (4S), the Cholesterol And Recurrent Events (CARE) study and 
the West Of Scotland Coronary Prevention (WOSCOPS) study222-224. 
The advent of the potent statins such as Atorvastatin, heralded numerous trials 
which suggested significant reduction of cardiovascular events in those with or 
without coronary artery disease. To name a few, ASCOT-LLA and the 4D 
studies were carried out in those patients without CAD and the MIRACLE and 
PROVE IT studies were carried out in those patients with CAD225-228. It was 
demonstrated that aggressive lipid lowering with Atorvastatin when compared to 
Simvastatin resulted in regression of atherosclerosis as seen by a reduction in 
the carotid artery intima-media thickness229. Thus there is unequivocal evidence 
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that aggressive lipid lowering is of definite benefit in primary and secondary 
prevention of CAD and that this is more effective with the more potent statins 
such as Atorvastatin. 
However it is now becoming increasingly evident that all the beneficial effects of 
statins may not be related to their ability to lower cholesterol. Indirect evidence 
from WOSCOPS, ASCOT and the CARE trials, in terms of subgroup analysis, 
has revealed that the relative risk reduction in cardiovascular mortality and 
morbidity in individuals in the statin group was still significant despite 
comparable serum cholesterol levels with the placebo group. This brought to 
fore the importance of the non lipid lowering actions of statins in cardiovascular 
protection14. This will be the subject of discussion in the next section. 
1.4.1 PLEIOTROPIC ACTIONS OF STATINS AND CARDIO-       
PROTECTION 
Pleiotropic actions of statins are defined as extrahepatic beneficial effects, that 
are dependent on mechanisms not related to its ability to lower cholesterol14. As 
already explained mevalonic acid levels are reduced as a result of the action of 
statins on the enzyme. However mevalonic acid is also a precursor for non-
cholesterol compounds such as isoprenoids which have numerous actions in 
cell signalling and cell survival (See figure 1.10). Inhibition of this isoprenoid 
synthesis has been the focus of much of the pleiotropic actions of statins. 
Though the pleiotropic actions may vary to some extent depending on the 
lipophylicity of the specific statin, the actions largely remain similar. Thus my 
discussion will relate to statins as a group.  
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The pleiotropic actions of statins in coronary artery disease has been shown to 
be mediated at the level of vascular endothelial cells, platelets and inflammatory 
cells and the myocardium itself 14. 
Statins improve endothelial dysfunction by increasing the expression of eNOS 
and thus increasing NO synthesis and also by reducing endothelin1 
production214. Simvastatin and Lovastatin have been shown to upregulate 
eNOS levels in human saphenous vein endothelial cells and this effect was 
abrogated by mevalonic acid thus suggesting a post transcriptional 
mechanism230. Human endothelial cells treated with Mevastatin demonstrate an 
up-regulation of eNOS and this is abolished by administration of geranylgeranyl 
pyrophosphate, which is downstream of mevalonate. In the same study 
inhibiton of Rho was associated with an upregulation of eNOS, thus suggesting 
that statins act by inhibiting Rho in the endothelium231. In a rabbit model of hind 
limb ischaemia, Simvastatin was shown to rapidly increase eNOS levels in the 
endothelial cells in a PI3k/AKT dependent manner and this was associated with 
a decrease in apoptosis232. Another mechanism of statin induced up-regulation 
was demonstrated in rat umbilical vein endothelial cells, wherein statin therapy 
was shown to inhibit caveolin formation (caveoli are negative regulators of 
eNOS) and also promoted HSP90 (Heat Shock Protein90) induced interaction 
of AKT with eNOS233. Another potential mechanism is related to the antioxidant 
property of statins. In an in-vivo rat model, Atorvastatin has been shown to 
improve endothelial function by inhibiting the expression of the p22phox subunit 
of NAD(P)H oxidase which is a precursor of ROS. It thus reduces oxidative 
stress. The associated reduction in reactive oxygen species (ROS) will reduce 
the scavenging of NO and thus result in enhanced availability of NO234. 
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Statins have also been shown to inhibit platelet activation and thus have an 
impact on thrombogenicity. In a normocholesterolemic mouse model, 
atorvastatin has been shown to up-regulate nitric oxide synthase-3 in platelets 
and this was associated with decreased platelet activation235. Statin induced 
increase in NO availability is also associated with a reduction in p-selectin 
expression and leukocyte adhesion. This may well play a role in reducing the 
inflammatory component of reperfusion injury236. 
Statins are protective when given acutely during either of two phases of 
myocardial ischaemia-reperfusion, the first being prior to ischaemia and the 
second being at the onset of reperfusion. Experimental models have 
demonstrated that the beneficial acute effects of statin can be seen to occur 
when administered from up to 72 hours prior to ischaemia-reperfusion till just 
prior to ischaemia or reperfusion237.  
Investigation of the potential cardioprotective pleiotropic effects of Statins was 
initiated in the 1990s by experiments which administered relevant statins pre-
ischaemically. One of the early experimental studies pointed to the role of 
endothelial Nitric Oxide Synthase (eNOS) as being a mediator in statin 
dependent cardioprotection. In these experiments using the isolated rat heart 
preparation, Simvastatin was administered 18 hours prior to ischaemia and 
statin treated hearts had an improvement in the left ventricular developed 
pressure (LVDP) and left ventricular contractility238. Similar results in the rat ex 
vivo preparation were demonstrated when Simvastatin was administered 20 
minutes prior to ischaemia. In this study it was shown that the cardioprotective 
effects are abolished by the administration of the NOS inhibitor, L-NAME (which 
was also administered 20 minutes prior to ischaemia). This group showed that 
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this effect is likely to be mediated by the inhibition of isoprenylation of G 
proteins that inhibit eNOS mRNA239.  
However it still remains unclear as to which is the precise mechanism of statin-
induced cardioprotection and various preclinical studies have tried to elucidate 
this. The following section will review the current available evidence for 
mechanistic insight into the pleiotropic actions of statins in the setting of 
myocardial reperfusion injury. 
Anti-inflammatory action: Following the initial studies demonstrating the role 
of eNOS mediated actions of statins, it was also demonstrated that Simvastatin 
given to diabetic mice for 5 days prior to being subjected to an in vivo model of 
ischaemia-reperfusion, significantly reduced the infarct size. This was also 
related to an increase in the availability of NO from eNOS and this was shown 
to be due to a reduction in the recruitment of PML cells and thus a reduction in 
inflammation240.  
Activation of RISK pathway: It had also been demonstrated previously that 
statins promote the differentiation of endothelial progenitor cells by activation of 
PI3 Kinase/ AKT pathway241. It was also shown that statins are responsible for 
AKT translocation to the membrane domain in endothelial cells and that this 
was dependent on PI3 kinase and the inhibition of mevalonic acid formation242. 
Following this Yellon’s laboratory demonstrated that acute administration of 
Atorvastatin at the onset of reperfusion resulted in a reduction in infarct size in a 
mouse Langendorff model of ischaemia-reperfusion. This was seen to be 
dependent on PI3 Kinase and AKT activation of eNOS8. Similar results were 
also reported in rat in vivo experiements when Simvastatin was acutely 
administered during reperfusion243. Indirect evidence of the involvement of PI3 
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Kinase/Akt pathway in statins induced cardioprotection was obtained when it 
was demonstrated that chronic administration of Atorvastatin resulted in loss of 
cardioprotection and that this was associated with an upregulation of PTEN 
(Phosphatase and tensin homolog deleted on chromosome ten) which is a 
known inhibitor of PI3K. However this cardioprotection was recaptured with a 
high dose of atorvastatin administered pre-ischaemically244. More recently 
Rosuvastatin administered prior to ischaemia in hypercholesterolemic pigs (in 
vivo recovery model of acute myocardial infarction) enhanced the levels of 
PKC, Erk2 and AKT/PKB378. 
Statins and Adenosine: Adenosine has been implicated as a mediator of 
statin-induced cardioprotection. This was first demonstrated in a 
hypercholesterolemic rabbit in vivo model where Pravastatin restored the ability 
to pre-condition hearts which was initially blunted by hypercholesterolemia. This 
was seen to parallel the activation of ecto5’nucleotidase in the ischaemic 
zone245. In a small study involving 35 hyperlipaedemic patients undergoing 
elective angioplasty for CAD, 3 month treatment with Pravastatin was 
associated with a reduction in myocardial enzyme release and reduction in ST 
segment shift peri-procedure and this was abolished by the adenosine blocker 
aminophylline246.  
In vivo experiments in a dog model of ischaemia-reperfusion injury have shown 
that when statins are administered pre ischaemically there is a dose dependent 
activation of PI3 Kinase and ecto 5’ nucleotidase during reperfusion. Ecto 5’ 
nucleotidase is a source of adenosine247. Adenosine, as already discussed, has 
an infarct sparing action by virtue of PI3 Kinase dependent activation of 
mitochondrial K+ ATP channels. However this study did not elucidate the exact 
mechanism of the interaction of statins and the ecto5’nucleotidase. In a further 
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attempt to unravel the mechanistic interaction of statins and adenosine, 
immunoblot experiments were carried out on mice hearts in the absence of 
ischaemia-reperfusion. This study revealed that treatment with statins is 
associated with activation of A1, A2a and A2b adenosine receptors which in 
turn phophorylate ERK1/2 and Akt/eNOS activation248. Further evidence of a 
potential role for adenosine mediated statin protection comes from rat heart ex 
vivo experiments carried out using a combination of atorvastatin and 
dipyridamole and also the effect of caffeinated coffee on statin mediated 
cardioprotection. Dipyridamole prevents reuptake of adenosine and was shown 
to work synergistically when administered with atorvastatin for three days prior 
to ischaemia and this effect was lost on administration of the adenosine 
receptor blocker aminophylline249. More recently caffeine, which is a known 
adenosine receptor blocker was shown to inhibit statin-induced cardioprotection 
when administered pre-ischaemically250. All these studies suggest that statin-
induced cardioprotection is mediated by adenosine by an as yet unknown 
mechanism. 
Statins and Isoprenoids: Another suggested mechanism of statin-
cardioprotection is the inhibition of mevalonic acid synthesis and its impact on 
the formation of isoprenoid intermediates. As already discussed statins inhibit 
the enzyme HMG CoA reductase (which is the rate limiting step in the 
cholesterol biosynthetic pathway). This enzyme is responsible for the formation 
of mevalonic acid which is the precursor of both cholesterol and isoprenoids 
such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. Isoprenoid 
synthesis is an independent mechanism from that of the cholesterol bio 
synthetic pathway14. The isoprenoids are responsible for activating Rho group 
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of proteins which have important cardiovascular actions. This synthetic pathway 
is summarized in figure 1.14. 
 
 
Fig 1.14: Mevalonic acid is the precursor of the isoprenoids Farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate. These isoprenoids are required for activation of Rho A 
which is an inhibitor of PI3K and eNOS. Adapted from Liao et al14. 
The Rho group of proteins are GTPases and are members of the Ras 
superfamily of small GTP binding proteins251. Of these the GTPases that have 
been characterized best are Rho, rac and Cdc42252. These Rho proteins cycle 
between active GTP bound state which is membrane bound and inactive GDP 
bound state which remains in the cytosol253. A key step in Rho activation is its 
binding to geranylgeraniol which is one of the isoprenoid intermediates of the 
cholesterol biosynthetic pathway. Rho A further mediates its actions via Rho 
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associated kinase (ROCK)201. ROCK has been shown to mediate hypoxia 
induced down regulation of eNOS in human pulmonary endothelial cells and 
this was reversed by the ROCK inhibitor Fasudil254. It has also been 
demonstrated in vascular smooth muscle cells that ROCK inhibits the activation 
of PI3 Kinase. Vascular smooth muscle cells were treated with insulin. Insulin 
was shown to inhibit the action of ROCK. Administration of Wortmanin (the PI3 
kinase inhibitor) reversed the action of insulin on the vascular smooth muscle 
cells but did not have an effect on ROCK inhibition. Thus it was demonstrated 
that PI3 Kinase inhibition is probably central to ROCK mediated actions255. 
Acute administration of the ROCK inhibitor Fasudil has been shown to be 
cardioprotective in an exvivo model of rat heart preparation and this was 
reversed by the PI3 Kinase inhibitor and the eNOS inhibitor256. This interaction 
of the Rho A/ ROCK pathway has been shown in figure 1.15. 
It has been shown that Mevastatin treated mice endothelial cells have an 
upregulation of eNOS expression which is reversed by treatment with 
geranylgeranylpyrophosphate and mevalonic acid231. Rosuvastatin 
administered orally for 48 hours prior to ischemia was also shown to be 
cardioprotective in an in vivo rat heart model and this was reversed by the 
administration of mevalonic acid and geranyl geranyl pyrophosphate. Western 
blot analysis revealed downregulation in active Rho A in the Rosuvastatin 
group257. 
Thus there exists both direct and indirect evidence that statin induced 
cardiovascular protection could be via the inhibition of Rho A/ ROCK pathway. 
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Fig1.15: Statins inhibit the formation of geranylgeranyl pyrophosphate which is required 
for the isoprenylation of Rho A. Activated Rho A inhibits the mRNA stability of eNOS and 
also activates Rho Kinases (ROCKS). ROCK is a negative regulator of PI3K/Akt and thus 
inhibits the phosphorylation of eNOS. GGPP: Geranylgeranyl pyrophosphate GG: 
Geranylgeraniol, GEF: guanine nucleotide exchange factors and GAP: GTPase activating 
proteins. 
Other mechnisms: Various other potential actions of statins have also been 
implicated. Cycloxygenase 2 has been implicated in statin induced 
cardioprotection by virtue of the upregulation of prostaglandins 6Keto- PGF1α 
and PGE2 production258 that is observed in rat ex vivo hearts when rats treated 
with Atorvastatin for three days prior to ischaemia showed an up regulation of 
Cycloxygenase-2 activity and inducible nitric oxide synthase activity (iNOS) 
both of which have been shown to offer cardioprotection by preconditioning259. 
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In separate experiments Aspirin administered prior to ischaemia or during 
reperfusion was shown to reverse the cardioprotection of atorvastatin. Aspirin is 
a non-selective inhibitor of Cycloxygenase enzyme260. This mechanism is 
believed to be downstream of eNOS activation.  
Previous experiments conducted in our laboratory have demonstrated that 
Atorvastatin administered at the onset of reperfusion in Langendorff perfused 
mice hearts activated other prosurvival kinases such as p44/42 MAPK and p38 
MAPK which then activated Heat Shock Protein 27 (HSP27)261. It was 
presumed that HSP27 activation resulted in protection by inactivation pro-
apoptotic proteins such as the caspase3, caspase9 and Fas and also by 
regulating the activity of AKT. However direct causation was not demonstrated 
in this study. 
It has also been shown that Atorvastatin activates peroxisome proliferators 
activated receptor gamma (PPAR γ) in rat cardiomyocytes and this has been 
seen to be as a consequence of prostaglandin activation262. In separate 
experiments the PPARγ activator Rosiglitazone was shown to be 
cardioprotective through the RISK pathway263. The combination of Atorvastatin 
and Pioglitazone (PPARγ activator) when administered prior to ischaemia has 
been shown to be additive in a rat in vivo model. However the downstream 
effectors appeared to be different. Atorvastatin induced eNOS phosphorylation, 
iNOS, Cycloxygenase-2 expression and cytosolic phospholipase expression 
while Pioglitazone mainly increased the expression of the cytosolic 
phospholipase379. 
More recently Rosuvastatin administered at reperfusion in 
normocholesterolemic and hypercholesterolemic rabbits (Langendorff perfused 
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hearts) was shown to reduce infarct size and this was associated with a 
reduction in the activity of matrix metalloproteinase-2 activity380. Also in a rat in 
vivo model recently pre-ischaemic administration of Atorvastatin has been 
shown to attenuate infarct size and also improve left ventricular function 
following myocardial ischaemia-reperfusion and this was associated with an up-
regulation of TNFα and Interleukin-10 mRNA381. 
These potential mechanisms have been summarized in table 1.01. 
Table 1.01: Pleiotropic actions of Statins in Cardiomyocytes. 
There is some evidence to suggest that these pleiotropic actions are important 
in the clinical setting. The ARMYDA study showed that seven day pre-treatment 
with atorvastatin 40 mg in patients undergoing elective PCI showed a reduction 
in peri procedural myocardial injury264. The recent ARMYDA-RECAPTURE 
study showed that reloading patients on chronic statin therapy who were 
undergoing elective PCI was associated with a better 30 day outcome265. The 
recent NAPLES study has also revealed that a single dose of 80 mg of 
Mechanism/Mediator Effector 
a. Anti-inflammatory action ↑eNOS, ↓leukocyte adhesion, ↓migration, 
TNFα and IL-10. 
b. RISK Pathway (direct) ↑PI3K/AKT/eNOS, Inhibit MPTP 
c. Adenosine ↑PKC/AKT/eNOS, ↑Mito K ATP, Inhibit 
MPTP 
d. Rho A/ROCK Inhibition ↑PI3K/AKT, ↑eNOS phosphorylation & 
mRNA stability. 
e. Cycloxygenase 2 ↑PGE2, ↑iNOS 
f. HSP27, MAPK ↑AKT, ↓caspase3 & 9. 
g. PPARγ ↑PI3K/AKT, eNOS, COX-2. 
h. ↓ Matrix metalloproteinase-2 ↓Cleaving of TroponinI and Myosin light 
chain protein. 
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Atorvastatin prior to PCI was associated with a reduction of periprocedural 
myocardial infarction266. 
1.4.2 ATORVATSTATIN AND CARDIOPROTECTION 
Atorvastatin, which is the subject of this thesis, has a molecular weight of 
1209.42 kDa218. It is a synthetic compound which is lipophylic and is a tissue 
specific HMG CoA reductase inhibitor with its primary action on the liver218. It is 
insoluble in aqueous solutions at a pH of 4.0, slightly soluble in ethanol and 
freely soluble in methanol218. It is rapidly absorbed when administered orally and 
has a half life of 20 to 30 hours in humans due to active metabolites218. 
 
There is now good preclinical and clinical data to suggest that the pleiotropic 
actions of statins may be involved in the acute cardioprotection from 
ischaemia–reperfusion injury and that a better understanding of the underlying 
mechanism with focus on the reperfusion phase will rationalise therapeutics. 
The various studies involving Atorvastatin have been summarized in tables 
1.02 and 1.03. 
Thus the focus of the studies presented in this thesis are an attempt to 
understand the mechanistic actions of atorvastatin on acute cardiovascular 
protection when administered during reperfusion. 
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Model Timing of administration               Result 
a. Isolated mouse heart At reperfusion ↓ infarct size. PI3k/AKT/eNOS 
activation. (Bell et al)8 
b. In vivo Porcine heart Prior to ischaemia (for 21 days) ↓ infarct size, good wall motion score on 
ECHO. (Lazar et al)267 
c. In vivo rat heart Prior to ischaemia (for 3 days) ↓ infarct size, Protection abolished by L-
NAME, the Nitric oxide synthase 
inhibitor. (Birnbaum et al)268 
d. Isolated mouse heart At reperfusion ↓ infarct size, ↑ PI3K/AKT, ↑ERK1/2 
and ↑HSP27. (Efthymiou et al)261 
e. Isolated rat heart Prior to ischaemia (for 14 days) Protection lost by chronic administration 
recaptured by acute supplementary 
dose, ↑ PTEN (PI3K  inhibitor ) on 
Chronic treatment ( Mensah et al)244 
f. Isolated rat heart Prior to ischaemia (for 3 days) ↓ infarct size, ↑PGE2 and PGF2α 
(Prostaglandins), ↑ eNOS & iNOS. 
(Birnbaum et al)258 
g. In vivo rat heart Prior to ischaemia (for 3 days) ↓ infarct size, ↑ iNOS & Cycloxygenase-
2 which is responsible for prostaglandin 
synthesis. (Atar et al)259 
h. In vivo rat heart Prior to ischaemia (for 3 days). Co- 
administered with sildanefil (NOS 
activator) 
Synergistic action with Sildanefil in 
reducing infarct size. (Rosanio et al)269 
i. Mouse heart Immunoblot Not Applicable ↑ERK1/2, ↑AKT, ↑ eNOS. All effects 
abolished by non-specific adenosine 
receptor antagonist 8-spt. (Merla et 
al)248 
j. In vivo rat heart Prior to ischaemia along with 
Dipyridamole (adenosine reuptake 
inhibitor) 
Synergistic action in infarct size 
reduction. (Ye et al)249 
k. In vivo rat heart Prior to ischaemia (for 3 days) ↓ Infarct size. This was abolished by 
caffeine, a non-specific inhibitor of 
adenosine receptor. (Ye et al)250 
l. In vivo mouse heart 2 days following ischaemia. Myeloperoxidase labelled Gadolinium 
revealed the anti-inflammatory action of 
Atorvastatin following myocardial 
infarction. (Nahrendorf et al)270 
m. In vivo rat heart (recovery) 2,7 or 14 days (during ischaemia and 
reperfusion) 
↓ Infarct size associated with up-
regulation of TNFα and IL-10 mRNA. 
(Sun et al)381 
n. In vivo rat heart For 3 days prior to ischaemia ↓ Infarct size, ↑ eNOS phosphorylation, 
↑ iNOS, ↑ COX-2 activity and ↑ 
cytosolic phospholipase activity. (Ye et 
al.)379 
Table 1.02: Animal studies with Atorvastatin in the setting of myocardial ischaemia-
reperfusion. 
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        Trial           No of Patients Study design Results 
a. ARMYDA264 153 Randomization to 
atorvastatin 40 mg or 
placebo for 7 days prior 
to elective PCI for stable 
angina. 
Significant reduction in 
periprocedural 
myocardial injury (not 
related to cholesterol 
lowering). 
b. Briguori et al271 451 Randomization between 
3 statins (including 
atorvastatin) and no 
treatment, for 3 days 
prior to elective PCI for 
stable angina 
Post procedure ↓CK-MB 
& ↓Troponin-I were 
significant in the statin 
group. 
c. NAPLES-II266 668 Randomization to 80 mg 
Atorvastatin versus no 
treatment for 24 hours 
prior to elective PCI for 
stable angina 
Significant reduction in all 
cause mortality. 
Subgroup analysis 
revealed that the most 
benefit was seen in 
patients with a high 
baseline CRP, 
suggesting anti-
inflammatory actions of 
statins. 
d. ARMYDA-ACS272 171 Randomization between 
80 mg of Atorvastatin 12 
h prior  to and a further 
40 mg prior to PCI and 
placebo in patients with 
Acute Coronary 
Syndrome. 
Composite end points of 
death, MI and 
revascularization were 
significantly lower in the 
statin group. 
Periprocedural 
myocardial injury was 
also significantly lower. 
e. ARMYDA-
RECAPTURE265 
383 Randomization between 
80 mg Atorvastatin 12 h 
prior to and 40 mg prior 
to PCI and placebo in 
patients on chronic statin 
therapy, having PCI. 
Significant reduction in 
the incidence of major 
adverse cardiac events. 
Table 1.03: Clinical trials with Atorvastatin in the acute setting. 
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2. BACKGROUND, AIMS AND HYPOTHESES 
2.1. STATIN AND GLUCOCORTICOID RECEPTOR 
As discussed in chapter1, Atorvastatin administered at reperfusion has been 
shown to have a protective effect via the RISK pathway8. The precise 
mechanism of this activation is still unclear. This may well be receptor mediated 
and it is interesting to note that statins bind with high affinity to the 
glucocorticoid steroid receptor (GCR) (See table 2.01) even at normal 
therapeutic doses273. 
Drugs Affinity to GCR  
Cortisol 0.5 
Prednisolone 3 
Atorvastatin 1 
Fluvastatin 3 
Lovastatin 15 
Pravastatin 8 
Simvastatin 2 
Rosuvastatin 7 
Table 2.01: Statins and affinity to GCR. Affinity expressed as bonded energy (Ki) in nmol. 
Lower the Ki greater the affinity to the receptor. Adapted from Marshall et al273. 
Furthermore a mouse in vivo model of ischaemia–reperfusion demonstrated 
that the glucocorticoid, Dexamethasone  when administered one hour prior to 
ischaemia was able to protect the heart and this was mediated by 
nontranscriptional activity of the GCR on the p85α subunit of the PI3K which 
subsequently resulted in the activation of eNOS274. 
Hypothesis 1 and aim 1: Thus it was hypothesized that Atorvastatin is 
cardioprotective when administered acutely during reperfusion and this is due to 
its interaction with the GCR. The aim of this study is to demonstrate a 
significant reduction in infarct size in an isolated Langendorff perfused rat heart 
model with the administration of Atorvastain at reperfusion and to demonstrate 
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that this would be abrogated by the non-specific glucocoticoid receptor 
antagonist, RU486. 
2.2 STATINS AND ADENOSINE 
As already described adenosine is a well studied cardioprotective 
agent166,178,179 and there are numerous preclinical studies to suggest that statin 
induced cardioprotection may well be due to its effect on adenosine 
metabolism245-250. However all this data has been with statins administered pre-
ischaemically and also both in the acute and the chronic setting. 
Hypothesis 2 and aim 2: Thus, it was hypothesized that Atorvastatin 
administered acutely during reperfusion exerted its effect through an 
adenosinergic mechanism. The aim of this study is to demonstrate infarct size 
reduction with Atorvastain administered acutely during reperfusion and prior to 
ischaemia in a Langendorff perfused rat heart model and to see if this is 
abrogated by the nonspecific adenosine receptor antagonist 8-Sulpho phenyl 
theophylline. 
2.3 STATINS AND RHO A 
Statins reversibly inhibit the enzyme HMG CoA reductase213,219. This results in 
a reduction of mevalonic acid. Mevalonic acid is a precursor for both cholesterol 
and isoprenoids such as geranylgeranyl pyrophosphate and farnesyl 
pyrophosphate, by divergent pathways14. These isoprenoids are required for the 
activation of Rho proteins and more specifically Rho A. Rho A further activates 
ROCK201. 
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Acute administration of ROCK inhibitors in the reperfusion phase has been 
seen to protect by activating the RISK pathway254. Also, statins administered in 
the pre-ischaemic phase have shown to protect by virtue of inhibiting the 
membrane translocation of Rho A231. 
Hypothesis 3 and aim 3: Thus, it was hypothesized that Atorvastatin when 
administered acutely during reperfusion protects the heart by virtue of inhibiting 
Rho A proteins, which are negative regulators of the RISK pathway. The aim of 
this study is to demonstrate infarct size reduction with Atorvastatin administered 
during reperfusion in a Langendorff perfused rat heart model and to show that 
this is abrogated by the addition of mevalonic acid. We also aim to quantify 
activated Rho A levels in statin treated hearts by Western blotting. 
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3. METHODS 
3.1 GENERAL 
All experiments were carried out in the laboratory premises of Hatter 
Cardiovascular Institute, University College London. All animal experiments 
were performed in accordance with the United Kingdom Home Office guidance 
as per the Animal (Scientific Procedures) Act of 1986, published by Her 
Majesty’s Stationery Office, London. All animals were obtained from the same 
supplier and were fed a standard pelleted diet with free access to water and 
were housed under the same conditions. 
3.2 CHOICE OF ANIMAL MODEL 
The isolated small mammalian heart probably represents the optimal 
compromise between the quality and quantity of data that can be obtained and 
its clinical relevance. Large mammalian hearts are more cumbersome to deal 
with and involve large amounts of perfusate and also the variability in the 
reproducibility of results275. 
My experiments were specifically designed to study pharmacological 
mechanisms of statin induced cardioprotection; such protection having already 
been demonstrated in rats by previous work carried out in our lab on Sprague 
Dawley rats244. We decide to use the rat heart due to its ease of handling when 
compared to smaller hearts such as those of mice and more specifically ease of 
recording intraventricular pressure275. Rat hearts are also by far the best 
characterized small animal model275. Rat hearts are however susceptible to 
ventricular fibrillation but it is usually easy to terminate these events if they do 
occur275,276. 
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Sprague Dawley rats had also been used in our lab to demonstrate 
mechanisms of preconditioning and postconditioning and also the effect of 
pharmacological treatments such as Glucagon Like Peptide-1, Erythropoetin, 
Omapatrilat etc173,277-279. It is thus clear that there is a significant amount of data 
to suggest that the Sprague Dawley (SD) rat heart is amenable to study the 
various phenomena associated with ischaemia-reperfusion injury. 
It is well known that age matched adult female rats are relatively protected from 
Ischaemia-Reperfusion injury280. This difference has been variously attributed to 
be due a muted inflammatory response in the female rat hearts280, an estrogen 
dependent mechanism of resistance to reperfusion injury281 and also due to the 
increase in p-Akt and phosphorylated Protein Kinase C-ε (p-PKCε) levels282. So 
I chose male SD rats to avoid this confounding factor.  
The isolated heart model is a highly reproducible model that can be studied 
quickly in large numbers and at a low cost275,276. It also allows the measurement 
of a large number of biological, morphological and pharmacological indices in 
the absence of various neurohormonal confounding factors associated with the 
invivo model275. However the major disadvantage of this model is that it is quite 
removed from the invivo model275 and thus extrapolation to the intact human 
body may not be always relevant. 
This model also allows for easy use of pharmacological agents in the perfusate 
to study the various effects on reperfusion injury275. It can also remain 
reasonably stable for many hours275,283 and experiments could be carried out in 
the face of events such as infarction associated pump failure or ventricular 
arrhythmias which would otherwise jeopardise an invivo experiment275.  
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We thus chose the isolated rat heart model with Langendorff perfusion using 
male Sprague Dawley rats for both infarct size measurement and protein assay 
by Western blot analysis. 
3.3 CHEMICALS AND DRUGS 
All constituents of the modified Krebs Henseleit buffer were purchased from 
BDH laboratory supplies (Merck Eurolab, Dorset, England). 2,3,5 triphenyl 
tetrazolium chloride (ttc) was purchased from Sigma Aldrich company (Dorset, 
England). RU486, 8-sulpho phenyl theophylline and Mevalonolactone were 
obtained from Sigma Aldrich Company and Atorvastatin was provided by Pfizer, 
USA. 
3.4 PREPARATION OF HEARTS FOR PERFUSION 
3.4.1 ANAESTHESIA AND ANTICOAGULATION 
All animals were weighed prior to experimentation. The animals were 
anaesthetized with intraperitoneal (IP) administration of Sodium Pentobarbital 
(55mg/kg) and were anticoagulated with 300 IU of Heparin by intraperitoneal 
administration276,284. The heparin was given as prophylaxis to prevent thrombus 
formation within coronary vasculature and the ventricles284. All animals weighed 
between 350 and 500 g. 
3.4.2 DISSECTION OF HEARTS 
Once the animals were adequately anaesthetized as assessed by the loss of 
pedal withdrawal reflex to pain, a skin incision was made at the level of the 
xiphoid sternum. The peritoneum was exposed and the incision was extended 
to the right and left costal margins and the diaphragm was perforated275,276. The 
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incision was then continued up the ribs along the right and left axillary lines. The 
entire anterior chest wall was then reflected upwards to expose the beating 
heart and the deflated lungs. The heart was then removed by transecting the 
descending thoracic aorta and was quickly transferred to a plastic boat 
containing chilled Modified Krebs Henseleit buffer at 4°C275,276. Timing was 
commenced at the point of cessation of corporeal circulation. The lung, thymic 
tissue and fatty tissue were dissected and the aorta was slit just distal to the 
origin of the brachiocephalic artery. These were then mounted on to the 
cannula attached to the Langendorff system and the ascending aorta was 
secured to the cannula with 2 × Mersilk sutures and the heart was retrogradely 
perfused through the ascending aorta. The time from cessation of corporeal 
circulation to the time of perfusion was less than 3 minutes in order to prevent 
inadvertent preconditioning as a result of perioperative delay285. 
 
Figure 3.01 : Heart cannulated on to the Langendorff apparatus 
3.5 LANGENDORFF PERFUSION 
The Langendorff system has been in use since 1895 and is a method of 
perfusing the isolated heart retrogradely through the aorta under constant 
pressure or constant flow244. The aorta is cannulated just above the sinus of 
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valsalva to ensure that the coronary ostia remain patent244. The hydrostatic 
pressure of the perfusate closes the aortic valve and the coronary bed is 
perfused. The perfusate then drains into the right atrium and right ventricle 
through the coronary sinus and is ejected out via the pulmonary artery244,275. 
Thus the left ventricle essentially remains empty during the entire procedure. 
3.5.1 THE LANGENDORFF SYSTEM 
The Langendorff system was purchased form ADInstruments Ltd, Oxfordshire, 
England. This is a self contained system for perfusion of small animal hearts. It 
is thermostatically controlled to maintain constant temperature of the perfusate 
and can be used to deliver perfusate at contant pressure or constant flow rate. 
The water jacket contains two separate reservoirs for perfusate and these are 
separated from the water jacket by means of cylindrical glassware. These 
reservoirs can be independently oxygenated with a mixture of 95% O2 and 5% 
CO2 275 (BOC gases, Manchester). The perfusate in the reservoirs is collected 
by a peristaltic pump that is regulated by a STH pump controller. The perfusate 
is then circulated to the cannulated rat heart. The perfusate pressure was 
maintained at a constant level of 70 mm of Hg by means of a physiological 
pressure transducer connected to a bridge amplifier. This maintains the 
pressure within an accuracy of ± 1 mm of Hg by means of a negative feedback 
circuitry. 
In order to measure the Left Ventricular End Diastolic Pressure (LVEDP) and 
also the LV Developed Pressure (LVDP), another physiological pressure 
transducer attached to a bridge amplifier was connected to an isovolumic latex 
balloon inserted via the left atrial appendage into the left ventricle. The balloon 
was inflated to maintain a constant LVEDP of between 5 and 10 mm of Hg. The 
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heart temperature was monitored by an implantable T-type thermocouple 
attached to a T type pod. This thermocouple was inserted into the pulmonary 
artery. The bridge amplifiers and the T type pod were connected to a pod 
expander which in turn was connected to an 8 channel Powerlab recorder 
which could run Chart software. 
Once the rat heart was cannulated on to the Langendorff system, perfusion was 
achieved retrogradely by maintaining the perfusate pressure at 70 mm of Hg by 
means of the pump controller. A perfusion pressure of 70-90 mm of Hg is 
physiological for invivo rat hearts but the higher end of this range is not entirely 
suited for the isolated perfused heart286. The flow resistance to crystalloid 
perfusate is much lesser than that of blood and thus higher pressures can lead 
to aortic valve incompetence and inadequate perfusion through the coronary 
bed and also there is a chance of tissue oedema with saline containing 
perfusate286. As a result a perfusion pressure of between 60 and 70 mm of Hg 
is considered adequate for the isolated rat heart model. The left atrial 
appendage was removed and the isovolumic latex balloon was inserted into the 
left ventricle and inflated to between 5 and 10 mm of Hg in order to maintain a 
constant LVEDP. The temperature probe was introduced into the pulmonary 
artery and the perfusate temperature was maintained between 37 and 37.4 °c 
by means of adjusting the thermostat. The temperature is tightly controlled in 
this range as hypothermia can reduce the rate of ischaemic damage and infarct 
size287,288 and also result in myocardial dysfunction. Transient heat stress can 
result in release of heat shock protein which in turn can alter the myocardial 
response to ischaemia289. The pH of the perfusate was maintained between 
7.35 and 7.45 by modifying the gas output. The pH was ascertained by means 
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of of a blood gas analyser (ABL 705, Copenhagen, Denmark). The CO2 in the 
gas is essential to maintain the pH276. 
A 3/0 silk suture on a round-bodied surgical needle was passed around the left 
main coronary artery and the ends of the suture were passed through a plastic 
tube which was plugged by another conical plastic tube to form a snare. The 
snare was made by cutting the ends off a plastic pipette. The exvivo rat heart is 
particularly amenable to regional ischaemia as the left main artery almost 
exclusively supplies the left ventricle and is visible along the epicardial surface 
in a groove close to the left atrial appendage286. Regional ischaemia was 
induced by tightening the snare and this was released to institute reperfusion284. 
The flow rate, temperature and developed pressure were monitored, displayed 
and recorded using a Powerlab system running Chart 4.0 software. Data was 
displayed using a Personal Desktop Computer. The various experimental 
protocols will be discussed later. 
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Fig 3.02: Langendorff System. A: Pump Control, B: Pressure transducer for LV, C: 
Reservoir for buffer/drug, D: Langendorff mount, E: Transducer for perfusion pressure & 
F: Thermal jacket. 
3.5.2 PERFUSION BUFFER 
The perfusion buffer was modified Kreb’s Henseleit buffer with the following 
composition (in mM/l): NaCl 118.5,NaHCO3 25, KCl 4.8, MgSO4 1.2, KH2PO4 
1.2, CaCl2 1.2 and Glucose 12.0284. Two main kinds of perfusate are typically 
used for the isolated perfused heart model. These are crystalloid based 
perfusate like the modified Kreb’s Henseleit buffer and blood based perfusate 
which could be in the form of whole blood pumped from a support animal or 
washed erythrocytes275. Crystalloid perfusates have ease of preparation, do not 
require additional perfusion systems and do not have the disadvantage of red 
cell haemolysis associated with blood based perfusates275. However the 
crystalloid perfusates have low oxygen carrying capacity with a high pO2 and 
thus require high perfusion rates and are also associated with increase 
incidence of tissue oedema275. However despite this the oxygenation of 
A 
D 
C 
B 
E 
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crystalloid buffers is sufficient to prevent any deterioration in contractile 
performance275. 
3.5.3 EXCLUSION CRITERIA 
The following exclusion criteria were used prospectively: 
(a) Prolonged time to perfusion > 3 minutes. This was to avoid any possibility of 
inadvertent preconditioning due to perioperative delay as already discussed. 
(b) Coronary flow rate of < 8 ml/min during stabilization. 
(c) Rate Pressure Product (RPP) of < 17,000 at stabilization. This was 
calculated by multiplying the Heart rate and developed pressure.  
The following exclusion criteria were applied retrospectively: 
(a) Hearts with an Infarct size/area at risk % of <12%. 
(b) Hearts with an area at risk/total heart % of < 40% or > 65%. 
3.5.4 PARAMETERS MEASURED 
3.5.4.1 CORONARY FLOW RATE AND PERFUSION PRESSURE 
The perfusion pressure was constant at 70 mm of Hg as already discussed. 
Thus the coronary flow rate altered based on coronary vascular bed resistance. 
This was essentially altered by physical ligation of the Left Coronary Artery 
during ischaemia and releasing this in reperfusion. Some pharmacological 
agents like calcium channel blockers and nitric oxide donors can also alter this 
resistance and thus coronary flow rate by virtue of coronary vasodilation284. 
Verification of occlusion was indicated by reduction in the coronary flow rate by 
> 30%290. 
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3.5.4.2 DEVELOPED PRESSURE AND RATE PRESSURE PRODUCT 
The developed pressure was measured by inserting an isovolumic balloon into 
the left ventricle. This also measured the heart rate. The rate pressure product 
(RPP) was obtained by multiplying the heart rate and developed pressure. The 
developed pressure and thus the RPP is a measure of ventricular 
contractility291. All hearts with an RPP of <17,000 at the end of stabilization 
were excluded244. A low RPP would represent non-physiological developed 
pressure and may well indicate some underlying mechanical dysfunction and 
thus were excluded prospectively284. It has been seen that the Langendorff 
model for isolated rat heart is stable at heart rates of up to 450 beats/min. 
However at higher heart rates the diastolic pressure rises and the developed 
pressure drops suggesting a decrease in ventricular contractility291. All my 
experiments were well within this upper physiological limit for the heart rate.  
3.6 MEASUREMENT OF INFARCT SIZE 
3.6.1 TETRAZOLIUM CHLORIDE STAINING 
Measurement of infarct size with vital stains is established practice to measure 
the extent of necrosis following coronary artery occlusion in experimental 
animals292. One such vital stain is 1,2,3 triphenyltetrazolium chloride (TTC). It is 
a well established approach for identifying and quantifying irreversible cellular 
injury. Normal myocardium reduces TTC to a red formazan stain while infarcted 
tissue remains unstained293. This is based on the activity of coenzymes, 
dehydrogenases and NAD/NADP levels in viable tissue when compared to 
infarct tissue293. This staining is however dependent on the duration of 
reperfusion for proper characterization of infarct and in the case of rat heart it 
has been shown to be a minimum of 60 minutes292,294.  
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At the end of the experiment protocol, the suture around the left coronary artery 
was tightened to ligate it and 1.5-2ml of 0.25% evans blue (in saline) was 
injected through the aortic cannula so as to delineate the area at risk from non-
risk area (blue)244,292. The hearts were then frozen in the -20°c freezer for 1-4 
hours and the hearts were sliced into 2 mm thick transverse slices (5 slices per 
heart) from apex to base244,284. These were then incubated in 1% TTC 
(phosphate buffer) for 12-15 minutes at 37°C284. The infarcted tissue remained 
pale while the viable tissue in the risk area stained brick red. The slices were 
then fixed in 10 % formalin for 12-24 hours284,292. The slices were then laid in 
order in between two glass sheets and scanned onto the PC as a Jpeg image in 
order to carry out analysis by planimetry. 
 
Figure 3.03: Scanned Image of Heart slices. A: Area at Risk (Pink), B: Non area at risk 
(Blue), C: Infarcted Tissue (White) 
3.6.2 INFARCT SIZE MEASUREMENT 
Infarct size analysis was carried out by two methods. Both these methods had 
comparable results with infarct size analysis and analysis of area at risk (AAR). 
The early group of experiments were analysed as follows: 
After the slices were fixed in formalin, they were laid out in order between two 
perspex sheets and traced onto acetate sheets. This was subsequently 
analyzed by computerized planimetry (Summa Sketch iii, Summgraphics, 
Seymour, CT)244. The acetates were photocopied following magnification by 
A 
C 
B 
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147%. The planimetry file was opened and caliberated in pixels using a 10×10 
mm graph sheet. The outlines were then drawn and the LV cavity was excluded 
and the remaining area was filled in with yellow to represent the full muscle. 
The area at risk was then traced and filled with green. The outline of the 
infarcted tissue was then traced and filled with red. A Microsoft office excel 
spread sheet was created using simple arithmetic formulae and the following 
were calculated: muscle volume, Area At Risk (AAR) as a percentage of whole 
muscle and the infracted tissue (I) as a percentage of AAR. Results were then 
presented as I/AAR %. 
The second method used with the latter group of the experiments was as 
follows: In this method the heart slices were laid out in order between perspex 
sheets and scanned onto a personal computer with a resolution of 600 dpi. The 
images were stored as Jpeg files and were analysed using the free-share 
software, Image j Version 5.1. The slices were trimmed by tracing and cutting 
the unwanted segments including the LV cavity by using the polygon selection 
function of the software. Then an RGB (Red-Green-Blue) split function was 
performed. Utilizing the slices in the red channel the slices were filled with red 
colour and area in pixels was measured to obtain total muscle area. The area at 
risk was obtained by subtracting the Evan’s blue area from the whole muscle 
using the red channel. The green channel was used to highlight the infarcted 
tissue and the cumulative infarcted area was obtained by selecting the 
highlighted infarcted tissue. The results were then represented as Infarct / AAR 
%.  The results were expressed as mean ± SEM (Standard Error of Mean) and 
one way ANOVA test (Graphpad Prism software, version 5) with Tukey post 
test correction was used to test significance. A ‘p’ value of <0.05 was 
considered significant. 
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Any hearts with an AAR of <40% or >65% were excluded from final analysis. 
Also hearts with an infarct size of <12% or >80% were excluded from the final 
analysis. 
3.7 WESTERN BLOTTING 
3.7.1 TISSUE PREPARATION 
Rat hearts were isolated and Langendorff perfused as already described. The 
protocol will be discussed in further sections. At the end of the experiment 
protocol, the suture around the left coronary artery was tied and the area at risk 
was delineated using Evan’s blue dye. This area was excised, snap frozen 
using a Wollenberger clamp (pre chilled in liquid nitrogen) and stored at -80°c 
for further analysis244. 
3.7.2 PROTEIN EXTRACTION 
The frozen heart samples were added to numbered röhren tubes. Each of these 
tubes were prefilled with 400 µl of the suspension buffer which consisted of the 
following: soduim chloride 100 mmol/l, TRIS 10 mmol/l (pH:7.6), ethylene 
diaminetetraacetic acid 1 mmol/l (pH:8.0), sodium pyrophosphate 2 mmol/l,, 
sodium fluoride 2 mmol/l, β-glycerophosphate 2 mmol/l, phenyl methyl sulfonyl 
fluoride 0.1µg/ml and 1 µg/ml each of aprotinin, leuceptin, protease inhibitor and 
trypsin inhibitor  Each sample was then homogenized with the tubes placed in a 
beaker of ice. The samples are then centrifuged at 10,000 revs/min and 4°c for 
10 minutes.  
 
The supernatant was then divided into two parts: one of 160µl and the other 
150 µl. The numbered samples containing 150 µl of the supernatant were 
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processed separately for assaying activated Rho A levels and this will be 
discussed later. 
Of the 160 µl of supernatant 10 µl was used for protein quantification. The 
remaining supernatant was then mixed with sample buffer containing TRIS 100 
mmol/l (pH 6.8), dithiothreitol (DTT) 200 mmol/l, Sodium dodecyl sulphate 2% 
(SDS), bromophenol blue 0.2% and glycerol 20% and placed in a heating block 
at 100 °c for 10 minutes. The denatured protein was the stored in the freezer at 
-80°c. 
3.7.3 PROTEIN ESTIMATION 
Protein concentrations were calculated by using Bicinchoninic acid (BCA) 
reagent assay. This assay is based on the biuret reaction of proteins, whereby 
proteins when placed in an alkaline medium containing Cu2+ ions, form a 
coloured complex between the copper ions and peptide bonds295.  BCA is a 
reagent that can form a 2:1 complex with Cu1+ ions and form a stable 
chromophore with an absorbance maximum at 562 nm295. The relationship 
between absorbance and protein concentration is linear and forms the basis for 
protein estimation.  
BCA was mixed with copper sulphate solution in a 50:1 ratio. 1 ml of this was 
then added to duplicate samples of known concentrations of Bovine Serum 
Albumin (BSA) in suspension buffer and also duplicate samples of the proteins 
to be estimated. A standard absorption curve was generated by using the BSA 
and measuring the absorbance with a spectrophotometer. The extracted protein 
absorption was then calculated and compared with the standard curve. A mean 
value of protein concentration was then calculated to enable equal loading of 
the polyacrylamide gel. 
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3.7.4 SAMPLE PROCESSING FOR ACTIVATED RHO A 
Activated Rho A is membrane bound and thus tissue samples need to be 
processed to release the membrane bound activated Rho A prior to estimation 
by gel electrophoresis. Thus Rho A activation was determined by using an 
affinity precipitation assay incorporating the Rho-binding domain (RBD) of 
rhotekin, which binds only to the active GTP bound form of Rho A296. 
As already explained the supernatant obtained from homogenization and 
centrifugation was divided into two samples of 160 µl and 150 µl respectively. 
The sample with 150 µl of supernatant was processed as follows to release 
activated Rho A: To each sample was added 20 µg of agarose conjugated 
Rhotekin-RBD (30 µl/sample). This slurry was obtained from Upstate cell 
signalling solutions, Lake Placid, NY. The samples were then incubated at 4°c 
for 45 minutes and then centrifuged at 4°c for 3 minutes at 15,000 revs/minute. 
The supernatant was discarded as the Rhotekin-RBD slurry would bind to the 
active Rho-A and settle to the bottom of the Eppendorff. The samples were then 
washed 3 times with the washing buffer (0.5 M/l NaCl, 1% Tx100, 10 mM of 
Magnesium chloride, 2ml of Sodium pyrophosphate, 400 µl of sodium fluoride, 
500µl of PMSF/AESBSF and 2.5 tablets of protease inhibitor). 
To this was then added 150 µl of suspension buffer (Section 3.7.2) and then 
150 µl of the sample buffer (Section 3.7.2), to obtain a final volume of 300 µl. 
The samples were then heated at 95-100 °c for 5 minutes to release the Rho A 
from the beads. The samples were then loaded on to the polyacrylamide gels at 
the same concentration as that obtained from BCA assay of the corresponding 
sample for total Rho A. 
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3.7.5 POLYACRYLAMIDE GEL ELECTROPHORESIS 
3.7.5.1 PRINCIPLES OF SODIUM DODECYL SULPHATE (SDS) 
POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) AND WESTERN 
BLOTTING 
SDS-PAGE is the most widely used method for qualitatively analyzing 
proteins297. The proteins separate on the polyacrylamide gel based on their 
relative molecular mass (size) and also native charge297. This method works on 
the principle that denatured proteins loaded on to a gel base will migrate when 
a current is passed through the gel and this migration and separation is 
dependent on (a) pore size of the gel (b) native charge of the protein and (c) the 
quarternary structure of the protein297.  
However DTT in the sample buffer reduces any disulphide bridges holding the 
tertiary structure of the protein together298. Thus the denatured protein opens up 
into a rod shaped structure and the native charge of the protein is swamped by 
the SDS298. The negatively charged protein –SDS complexes move towards the 
anode when the current is passed. As their charge per unit length is the same 
they move in the running gel with the same mobility297. The proteins in the 
running gel separate by virtue of the molecular sieving properties of the running 
gel whereby the smaller proteins are able to pass through the pores while larger 
proteins are retarded by frictional resistance297. A stacking gel is used to 
concentrate the protein sample so as to provide sharper bands in the running 
gel and this works on the principle of isotachophoresis297. The principle of 
isotachophoresis works on the basis that negatively charged glycinate particles 
in the buffer have lesser electrophoretic mobility than the SDS-protein 
complexes which in turn are less mobile than the chloride ions. Field strength is 
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inversely proportional to conductivity which in turn is directly proportional to 
concentration297. Thus the SDS-protein complexes are at smaller concentration 
and form a tight band in the stacking gel. 
Once the proteins are separated in the gel, they are transferred to a 
nitrocellulose sheet. The epitopes of the proteins are now accessible to 
immunoblotting. 
3.7.5.2 GEL PREPARATION 
The running gel (12.5% Acrylamide gel) was prepared by mixing 12 ml of 
deionised water, 15 ml of 30% Acrylamide and 9 ml of Running gel base (1.5 M 
of TRIS and 0.4% SDS mixed in deionised water, pH 8.8). To this was added 
40µl of NNN-tetraethylethylenediamine (TEMED) and 200 µl of Ammonium 
persulphate (APS) (10%). The TEMED quickly polymerizes the acrylamide to 
form a gel. The running gel was then rapidly transferred to the vertical plate 
assembly and was then topped up with a 50:50 dilution of deionised water and 
isopropanol. This was allowed to set for 30 min. The stacking gel (5% 
Acrylamide gel) was then prepared by mixing 2 ml of 30 % acrylamide, 8% 
bromophenol blue, 3ml of stacking gel base (0.5 M TRIS and 0.4 % SDS in 
deionised water, pH of 6.8). This was then mixed with 24 µl of TEMED and 120 
µl of 10 % APS.The mixture of deionised water and isopropanol was emptied 
from the vertical glass plates and the combs were removed. The stacking gel 
was then added on top of the running gel and allowed to set for 10 minutes. 
Once the stacking gel had set the combs were removed to enable the wells to 
fill up with running buffer. 
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3.7.5.3 GEL ELECTROPHORESIS 
Precision Plus Protein Standard marker was added to the first well (15µl) and 
appropriate volumes (as calculated by protein curve) of samples were added 
into corresponding wells. The rig was then placed in the tank and the tank was 
filled with running buffer. The gel was allowed to run for 2 hours at 200 V, until 
the marker has spread out sufficiently at the level of the target protein. 
3.7.5.4 PROTEIN TRANSFER 
Once the gel was satisfactorily run, the gel was taken out and the stacking gel 
was removed. The gel was then transferred to a Whatman paper placed on the 
electrophoretic cassette and this was done while the cassette was immersed in 
transfer buffer which was composed of 20% methanol in deionized water and 
10x transfer buffer (150 mM of Glycine and 20 mM of TRIS base)299. An 
equivalent size Hybond ECL nitrocellulose membrane was then cut and placed 
on the gel while in the transfer buffer and the top right corner was snipped to 
identify well number one299. Another Whatman paper soaked in transfer buffer 
was then placed on top of this nitrocellulose membrane and the cassette was 
closed and mounted in a tank filled with transfer buffer. Transfer was allowed to 
occur overnight at 0.1 Amps. Satisfactory transfer was confirmed using 
Ponceau red staining. 
3.7.6 IMMUNOBLOTTING 
The membranes were washed on a mechanical shaker with washing buffer (50 
ml of 10X TBS, 450 ml of deionized water and 0.5 ml of Tween 20. The 
membranes were then covered with blocking buffer (washing buffer + 5% 
skimmed milk) for one hour. The blocking buffer was used to reduce non-
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specific binding sites and also to promote renaturation of antigenic sites300. 
Following blocking, the membranes were washed for 3 × 5 minute periods in 
washing buffer. 
3.7.6.1 PRIMARY ANTIBODY 
The washed membranes were incubated with primary antibody (concentration 
of 1:200 dissolved in 5% Bovine Serum Albumin). The membranes were 
incubated overnight in the cold room so as to ensure good quality blots. 
The primary antibody, Rho A (26C4), was obtained from Santa Cruz 
Biotechnology. This antibody is a mouse monoclonal antibody raised against an 
epitope of Rho A of human origin. In order to obtain an internal control, the blots 
were probed for β-actin300. The primary antibody for β-actin was mouse 
monoclonal anti β-actin antibody which was purchased from Sigma-aldrich 
chemicals. The membranes were stripped with 0.2 M Sodium hydroxide and 
stripping buffer before probing for β-actin. 
3.7.6.2 SECONDARY ANTIBODY 
The membranes were rinsed with TBS and the specific secondary antibody was 
added at a concentration of 1:1000. This secondary antibody is usually coupled 
with a Horse Radish Peroxidase (HRP). Membranes were then developed using 
an enhanced chemiluminescence technique (ECL Western blotting detection 
system, Amersham). Bands on the membranes were visualized using 
autoradiography onto Kodak films (Herts, England).  
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3.7.7 QUANTIFICATION AND STATISTICAL ANALYSIS  
The films were scanned and saved a jpeg images. The blots were then 
analysed with ImageJ software and relative densitiometry values were 
calculated and converted as a ratio of the β-actin density. Values were 
expressed as mean ± SEM. Statistical significance was measured using one 
way ANOVA test (Graphpad Prism software, version 5.0) with Tukey post test 
correction and a ‘p’ value of <0.05 was considered significant. 
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4. MODEL CHARACTERIZATION AND VALIDATION 
4.1 ISCHAEMIA/REPERFUSION PROTOCOL 
The ischaemia/reperfusion protocol that involves transient ligation of the 
coronary artery followed by reperfusion, is the choice of model for studying 
therapies and outcomes from ischaemia-reperfusion301.  
An optimum duration of ischaemia and reperfusion was arrived upon based on 
available literature and the protocol followed in our lab. Regional ischaemia was 
induced by ligating the left coronary artery with a suture and snare and 
reperfusion was reinstated by releasing the snare302. 
Rat hearts subjected to brief periods of ischaemia (30 to 35 minutes) regained 
contractile activity after institution of reperfusion. However if the period of 
ischaemia was 45-55 minutes the hearts do not regain their contractility303. It 
has also been shown that the time taken for repletion of myocardial ATP during 
reperfusion is dependent on the duration of ischaemia304. In addition it has been 
shown that a minimum of 30 minutes of ischaemia is required to demonstrate 
complete loss of glycogen stores in rat hearts305. The duration of ischaemia also 
has an effect on the formation of well defined infarcted tissue which is 
subsequently delineated by the use of TTC. TTC is able to detect infarcted 
tissue with ischaemic episodes lasting for 30 minutes or more306. A number of 
early studies have also shown an increase in adrenergic activity in the 
ischaemic myocardium and thus the efflux of H3+ tagged Nor-adrenaline has 
been used as a surrogate marker of the degree of ischaemia. It has been 
demonstrated that the efflux peaks at reperfusion after 30 minutes of ischaemia 
in rat hearts when glucose has been used in the perfusate, indirectly showing 
the adequacy of ischaemia307. Furthermore our lab has successfully used a 
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model involving 35 minutes of regional ischaemia284. Thus, in order to balance 
the reproducibility of infarction with the requirement for adequate staining with 
TTC, the duration of ischaemia was set at 35 minutes after a 40 minute period 
of stabilization. 
Reperfusion following ischaemia is essential for myocardial salvage which is 
manifested as a reduction in infarct size. This has been demonstrated in rat 
hearts, whereby the size of infarction was 60 % less in those hearts which had 
been reperfused when compared to those with permanent ischaemia. This 
infarct sparing was perceptible within the first hour of reperfusion308. The 
duration of reperfusion is also important as it is required for the washout of 
dehydrogenases which mediate the TTC staining. It has been shown in rat 
hearts (in vivo) that a period of 60 minutes or more of reperfusion is essential to 
obtain homogenous pale white delineation of the infarcted myocardium and any 
period lesser than 60 minutes results in patchy delineation of infarct tissue 
which makes it difficult to accurately assess infarct to risk ratio292. However the 
period of ischaemia in the in vivo experiments was at least 90 minutes. As we 
used a rat langendorff method with a 35 minute duration of ischaemia, we 
chose a reperfusion period of 120 minutes which has been shown to produce 
reproducible results for infarct analysis in our lab284. However recently it has 
been demonstrated that 60 minutes of reperfusion is also sufficient to assess 
infarct size in rat heart Langendorff model294. 
Atorvastatin and various inhibitors were administered during the last 5 minutes 
of ischaemia and for the first 15 minutes of reperfusion except in the 
experiments involving pre-ischaemic administration of Atorvastatin. This was 
done so as to allow the drug to diffuse into the cells and activate/inactivate any 
potential targets, by the time reperfusion is established. This is because any 
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pharmacological manipulation to attenuate ischaemia-reperfusion injury needs 
to be present in the first few minutes of reperfusion as this is the critical window 
of cardioprotection127,294. This has been demonstrated in isolated perfused rat 
hearts whereby administration of sangliferin A (inhibitor of MPTP) at the 
beginning of reperfusion attenuates infarct size but not when administered after 
the first 15 minutes of reperfusion127. Thus in my experiments Atorvastatin was 
perfused towards the end of ischaemia to ensure its availability at the onset of 
reperfusion. 
In the case of pre-ischaemic administration of Atorvastatin, the hearts were 
perfused with the drug for a total duration of 20 minutes during stabilization, 
followed by a 10 minute washout period prior to ischaemia. 
4.2 ISCHAEMIC PRECONDITIONING 
In order to validate my model, I compared the infarct sizes from a standard 
ischaemia –reperfusion protocol with that of a preconditioning protocol. The 
results were compared with previous work that used a similar model.  
Ischaemic preconditioning of the myocardium is a phenomenon whereby brief 
periods of sublethal ischaemia would delay the onset of necrosis during 
subsequent lethal ischaemic insult21. In cardiovascular research this translates 
as a significant and highly reproducible reduction in infarct size. The 
preconditioning protocol consisted of two cycles of 5 minute periods of global 
ischaemia interspersed with a 10 minute period of reperfusion, prior to regional 
ischaemia. The duration of the regional ischaemia and reperfusion period was 
the same as that of the standard ischaemia-reperfusion protocol. For the 
ischaemia–reperfusion protocol we used a stabilization duration of 40 minutes 
followed by a 35 minute period of regional ischaemia and a 120 minute period 
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of reperfusion. A total of 18 hearts were used. 3 hearts were excluded for 
technical reasons and data from 5 hearts was excluded either due to very low 
infarct size (<12%) or due to low risk zone (<40%).   
Hearts were randomly assigned to the ischaemia-reperfusion protocol or to the 
preconditioning protocol as per figure 4.01. 
A. Ischaemia-reperfusion Protocol 
 
     
 
                                                     
    0                                            40                                90                                                           195 Minutes 
B. Preconditioning Protocol 
 
 
 
 
 
  0             10   15    25   30      40                                90                                                           195 Minutes 
Figure 4.01: Protocols for standardization of the model. Legend: P1 and P2: 
Preconditioning cycles 1 & 2 of global ischaemia (5 minutes each). R1 & R2: Reperfusion 
1 & 2 after P1 & 2 respectively (10 min each). 
At the end of the experiments the hearts were stained with TTC and infarct size 
measured. Data were represented as % Infarct/AAR and a ‘p’ value of <0.05 
was considered significant. Tests of significance were performed using 
unpaired t-test.  Although the baseline morphometrics were not used to validate 
the model, there was no significant difference in any of the baseline parameters 
between the control group and the preconditioned group. The results are 
presented in table 4.01, 4.02 and 4.03 & figure 4.02. 
 
 
Stabilization (40 min) Ischaemia (35 
min) 
Reperfusion (120 min) 
Stabili
zation 
(10 
min) 
Ischaemia (35 min) Reperfusion (120 min) R1 R2 
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Baseline Characteristics 
Groups Number Body weight 
Control 6 445±21 
Preconditioning 4 361±20 * 
Table 4.01: Body weight (gms ± SEM). * 'p’ value of < 0.05 when compared to control. 
 
 
Groups S10 S30/P2 I5 I30 R5 R30 R120 
Control 14±1.3 13.5±1.4 8±1 7.3±0.8 14.5±1 13±0.7 8.7±1 
Preconditioned 14±1.3 14.5±2.2 8±1.3 9±1.3 15.6±1.5 13.5±1.2 6.8±0.8 
Table 4.02: Coronary flow rate (ml/min ± SEM). S: Stabilization, I: Ischaemia, R: 
Reperfusion, P2: Preconditioned cycle 2. 
 
 
 
Table 4.03: Rate Pressure Product. S: Stabilization, I: Ischaemia, R: Reperfusion, P2:    
Preconditioned cycle 2. 
 
 
Groups S10 S30/P2 I5 I30 R5 R30 R120 
Control 
27378± 
3832 
25307± 
2341 
9937± 
986 
16470± 
1195 
26336± 
1525 
25009± 
2407 
14797± 
3312 
Preconditioned 
44663± 
6263* 
31404± 
3941 
18943± 
3941 
25148± 
4506 
34062± 
4597 
28957± 
2289 
19222± 
4951 
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Fig 4.02 : The infarct size as a % of Area At Risk for the control (Ischaemia-reperfusion 
group) was 45% ±  4% and the infarct size in the preconditioned group was 19 % ±  1%. 
The infarct size reduction was significant with a p value of 0.003. 
The infarct size in the control group was 45±4% and in the preconditioned 
group was 19±1%. The infarct size reduction with preconditioning was 
significant (P value of < 0.01). These results were consistent with previous data 
obtained in our lab273. Thus I was able to successfully demonstrate that the 
model is suitable to obtain reproducible results to demonstrate myocardial 
protection. 
4.3 ATORVASTATIN INDUCED CARDIOPROTECTION IN THE SETTING OF 
ISCHAEMIA-REPERFUSION 
As part of the process to validate the model in my hands, I also verified that 
Atorvastatin when administered acutely during reperfusion was able to reduce 
the infarct size in Langendorff perfused rat hearts. 
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Di Napoli et al. first demonstrated that Simvastatin perfused pre-ischaemically 
in Langendorff perfused rat hearts attenuated reperfusion injury by a nitric oxide 
dependent mechanism239. Bell et al demonstrated in an ex vivo model of mouse 
heart that Atorvastatin when acutely administered during reperfusion reduced 
the infarct size and this was by upregulation of the RISK pathway8. By using 
Fluvastatin administered intravenously prior to ischaemia, Teifenbacher et al 
(rat in vivo model), demonstrated a reduction in infarct size309. Wolfrum et al 
also demonstrated in a rat in vivo model that acute administration of 
Simvastatin during reperfusion injury results in a reduction in infarct size by 
targeting the RISK pathway243. 
In order to demonstrate cardioprotection with acute administration of 
Atorvastatin at reperfusion, the hearts were divided into 3 groups as follows: 
(a) Control Hearts: Which underwent a standard ischaemia-reperfusion protocol 
(Protocol A in figure 4.01). 
(b) Vehicle Control (Methanol): Atorvastatin is only soluble in methanol. Thus to 
demonstrate that the vehicle did not contribute to the cardioprotection, the 
group consisted of hearts which were perfused with methanol for the last 5 
minutes of ischaemia and the first 15 minutes of reperfusion. This was used at a 
concentration of 0.1%, and this concentration was not associated with any 
significant protection in an isolated perfused mouse heart8 (Figure 4.03). 
(c) Atorvastatin group: In this group the hearts were perfused with Atorvastatin 
for the last 5 minutes of ischaemia and the first 15 minutes of reperfusion. 
Atorvastatin was used at a dose of 50 µmol/l8 (Figure 4.03). 
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       0                                            40                         70             90                                                       195 Minutes 
Fig 4.03: Protocol for administration of Vehicle (Methanol at a concentration of 0.1%) and 
Drug (Atorvastatin at a dose of 50 µmol/L). 
At the end of the protocol the hearts were analysed for infarct size as already 
described and expressed as Infarct/AAR % and tested for significance by one 
way ANOVA testing (Graphpad prism software, version 5.0) and Tukey post 
test comparison and a p value<0.05 was considered significant. 
Baseline Characteristics 
Groups Number Body weight 
Control 8 424±21 
Methanol (Vehicle) 6 461±18 
Atorvastatin 7 434±15 
Table 4.04: Body weight (gms ± SEM). 
 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Control 14±1 13±1 8±0.8 7±0.6 14±0.8 12±0.7 8±0.9 
Methanol 16±1 16±1 8±0.9 8±1 15±0.7 12±0.9 6±0.6 
Atorvastatin 16±0.8 14±0.3 7±0.3 6±0.4 15±1 11±1 5±0.3* 
Table 4.05: Coronary flow rate (ml/min ± SEM). S: Stabilization, I: Ischaemia, R: 
Reperfusion.* p<0.05 when compared to control. 
 
 
 
Drug/ 
Vehicl
e (20 
min) 
Stabilization (40 min) Ischaemia (30 
min) 
Reperfusion (105 min) 
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Table 4.06: Rate Pressure Product. S: Stabilization, I: Ischaemia, R: Reperfusion, 
There were no significant differences in the baseline haemodynamic data for all 
the groups (Table 4.04, 4.05 and 4.06). The mean infarct size with the control 
group was 48±5%, the methanol group was 49±4% and the Atorvastatin group 
was 26±5% (figure 4.04). This reduction in infarct size with Atorvastatin was 
significant when compared to both the control groups and the methanol groups 
( p value of <0.05). 
 
Fig 4.04: Infarct size reduction with Atorvastatin was significant with a p value of <0.05, 
when compared with both control and vehicle. There was no significant difference 
between the control hearts and the vehicle perfused hearts. 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Control 
31077 
±3918 
27563 
±3232 
11369 
±2159 
18517 
±1796 
27649 
±1796 
26330 
±2169 
16313 
±2782 
Methanol 
30097 
±5431 
30020 
±4149 
13807 
±2782 
21222 
±3190 
26025 
±2532 
24290 
±3546 
14786 
±4390 
Atorvastatin 
35863 
±4929 
32363 
±2946 
15424 
±2406 
16170 
±2438 
23703 
±2672 
24027 
±2409 
11411 
±1696 
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These results thus demonstrate that Atorvastatin, administered acutely during 
reperfusion, is able to protect the Langendorff perfused rat heart. This is 
comparable to the results of previous work in a Langendorff perfused mouse 
model8,261. It is thus apparent that the infarct sparing action of statins must be 
as a direct result of its action on the myocardium and  independent of its activity 
on platelets and inflammatory cells (as the perfusate lacks either of these) and 
also independent of its cholesterol lowering action, as any of these effects 
require chronic administration of statins over a period of hours to days rather 
than the 20 minutes used here. We thus set out to explore the possible 
mechanisms/receptor targets of statin induced cardioprotection in the acute 
setting. 
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5. ATORVASTATIN AND THE STEROID RECEPTOR 
5.1 AIMS AND HYPOTHESIS 
Statins acutely administered at reperfusion have been shown to exert a 
cardioprotective effect in isolated perfused mouse hearts and in vivo rat 
hearts8,243. This effect seems to be due to the activation of the pro-survival 
pathway called the RISK pathway8.243. Corticosteroids such as dexamethasone 
have also been shown to protect the heart when administered acutely during 
reperfusion and this effect is exerted via the RISK pathway274,310. This action of 
the steroids has been shown to be a non-transcriptional action of the gluco-
corticoid receptor (GCR)274,310. Statins have also been shown to bind to the 
glucocorticoid receptor at therapeutic doses. Thus we investigated the 
hypothesis that Atorvastatin protects the rat ex vivo heart preparation when 
administered acutely during reperfusion and that this acute cardioprotective 
action is mediated via the GCR. 
5.2 METHODS 
As described in chapter 3 and 4 (methods & model characterization), 
Langendorff perfused rat hearts were subject to 35 minutes of regional 
ischaemia followed by 120 minutes of reperfusion. This protocol was preceeded 
by a 40 minute period of stabilization. At the end of the experimental protocol 
the hearts were analysed for infarct size as a percentage of the Area at Risk 
(AAR) using planimetry and data was represented as mean± SEM . The data 
was assessed for statistical significance using one way ANOVA test with a p 
value of <0.05 considered significant. 52 hearts were used of which one heart 
was lost due to technical problems. Data from 13 hearts were not included due 
to significant precipitation of Atorvastatin in the Langendorff system, large risk 
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zone and small infarct size ( i.e., outside the predefined exclusion criteria). This 
problem with precipitation of the drug was overcome by heating the buffer at 
37°C while dissolving the drug and also by minimizing the amount of gas 
required to maintain the pH in physiological range (Forceful gassing was 
associated with greater degree of precipitation). 
The hearts were randomly assigned to the following groups based upon the 
drugs administered during reperfusion (Figure 5.01): 
(a) Controls: Standard ischaemia –reperfusion protocol. (Protocol A in figure 
4.01). 
(b) Ethanol as vehicle for the GCR blocker RU486. Ethanol was used at a 
concentration of 0.005%. 
(c) Methanol (vehicle for atorvastatin) was used at a concentration of 0.1%. This 
was used as the control group. 
(d) RU486 (Mifepristone), which is the GCR blocker, at a dose of 1µmol/l. 
RU486 was shown to block the glucocorticoid receptor activity at this dose 
when used to treat primary adult rat cardiomyocytes311. 
(e) Atorvastatin (ATV) at a dose of 50 µmol/l. Atorvastatin was dissolved in 
methanol at a dilution of 5 mg per 100 µl of methanol. This dose was 
demonstrated to be cardioprotective in a mouse ex vivo model8. 
(f) Combination of Atorvastatin and RU486 at the same concentration as stated 
above. 
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       0                                            40                         70             90                                                       195 Minutes 
Figure 5.01: Protocols; Vehicle: Ethanol 0.005% or Methanol 0.1%.                                    
Drug: Atorvastatin, RU486 and ATV+ RU486 
5.3 RESULTS 
No significant difference existed between the various groups during stabilization 
with respect to coronary flow rate, developed pressure and rate pressure 
product with the exception of the ethanol group (tables 5.01, 5.02 and 5.03). 
These hearts had a significantly better flow rate during stabilization when 
compared to the control group. However all drug treatments and vehicle 
treatments occurred acutely during reperfusion and thus this difference would 
not be influenced by any drug treatment and the noticed difference is probably 
purely by chance.  
Baseline Characteristics 
Groups Number Body Weight (gms±SEM) 
Control 8 424±21 
Methanol 7 452±17 
Ethanol 10 443±17 
Atorvastatin (ATV) 7 433±15 
RU486 8 424±12 
ATV+RU486 6 411±18 
Table 5.01: Body Weight (gms±SEM).  
 
 
 
Drug/ 
Vehicl
e (20 
min) 
Stabilization (40 min) Ischaemia (30 
min) 
Reperfusion (105 min) 
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Table 5.02: Coronary Flow rate (ml/min ± SEM). S-stabilization, I-Ischaemia & R-
Reperfusion. * p<0.05 when compared to control. 
 
 
Table 5.03: Rate Pressure Product. S-stabilization, I-Ischaemia & R-Reperfusion 
 
 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Control 14±1 13±1 8±1 8±1 14±1 12±1 8±1 
Methanol 16±1 16±1 8±1 8±1 14±1 11±1 6±1 
Ethanol 18±1* 15±0.3 7±1 7±0.4 15±0.3 10±1 6±0.4 
ATV 16±0.4 14±1 7±0.3 6±0.4 14±1 11±1 5±0.3 
RU486 17±1 15±0.3 8±1 7±1 15±1 11±1 7±1 
ATV+RU486 16±1 15±1 7±1 8±1 14±1 10±1 6±1 
Groups S10 S30 I5 I30 R5 R30 R120 
Control 
31077± 
3918 
27314±
3301 
11294±
2175 
18517±
1796 
27649±
1796 
26387
±2158 
16314±
2781 
Methanol 
31649± 
4993 
32426±
4627 
17180±
4112 
21719±
2741 
27599±
2657 
24748
±3032 
13913±
2433 
Ethanol 
39686± 
3403 
34490±
2934 
16621±
3057 
20135±
2247 
26188±
2457 
21492
±3085 
14892±
2198 
ATV 
35863± 
4929 
33955±
2733 
15424±
2406 
16170±
2438 
23703±
2672 
24027
±2409 
11411±
1696 
RU486 
32124± 
3943 
35715±
2618 
15529±
1923 
19714±
1286 
29520±
1283 
29269
±1638 
19784±
1432 
ATV+RU486 
39664± 
1430 
35955±
1426 
18540±
2887 
24062±
2772 
26009±
2822 
26032
±1582 
15640±
1075 
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Figure 5.02: When compared with the control, all groups except for the methanol group, 
showed significant reduction in infarct size including the group perfused with ethanol 
(vehicle for RU486). 
 
The infarct size in the various groups were as follows: (a) Control 48±5 % (b) 
Methanol (vehicle for ATV) 49±3% (b) Ethanol (Vehicle for RU486) 30±4% (c) 
Atorvastatin (ATV) 26±5% (d) RU486 24±2% (e) ATV + RU486 25±7%. The 
ethanol-treated hearts were significantly protected with a p value of <0.05 
versus control hearts. The ATV treated hearts and the RU486 treated hearts 
were significantly protected with p values of <0.05 and <0.01 respectively. 
Hearts treated with a combination of ATV and RU486 were also significantly 
protected with a p value <0.05. 
From the above results it would appear that ethanol which was used as the 
vehicle for RU486 itself is cardioprotective. Thus in order to establish if RU486 
abrogated the infarct sparing action of Atorvastatin, the experiments were 
repeated by dissolving RU486 at the same dose in 0.1% methanol. For this set 
of experiments, 31 hearts were used. One heart was excluded as it did not 
attain baseline characteristics at the end of stabilization and infarct data from 4 
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hearts were excluded due to small infarct size (tables 5.04. 5.05 &5.06 and 
Figure5.03). 
Baseline Characteristics 
Groups Number Weight ±SEM (gms) 
Methanol  Control 8 469±23 
Atorvastatin 6 437±17 
RU486 6 479±38 
Atorvastatin + RU486 6 474±40 
Table 5.04: Mean Body weight (gms). 
 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol- Control 17±0.9 16±0.9 7±0.5 7±0.5 14±0.5 12±0.9 6±0.6 
Atorvastatin 15±0.6 14±0.3 7±0.3 6±0.5 16±0.9 12±2 5±0.4 
RU486 18±1.5 16±1 7±0.6 6±0.8 17±2 11±2 6±1 
Atorvastatin + 
RU486 18±1 16±0.6 8±0.4 7±0.6 14±0.9 10±1 6±0.6 
Table 5.05: Mean Coronary Flow Rate (ml/min ± SEM). S-stabilization, I-Ischaemia & R-
Reperfusion. 
Table 5.06: Mean Rate Pressure Product. S-stabilization, I-Ischaemia & R-Reperfusion. 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol- Control 
32292± 
4266 
28237± 
2092 
12154± 
1223 
19067± 
2245 
24434 
±2329 
23517 
±2595 
13294± 
2091 
Atorvastatin 
34708± 
5670 
32439± 
3484 
15045± 
2811 
17090± 
2672 
25630 
±2190 
25709 
±2040 
12030± 
1868 
RU486 
35352± 
2581 
37240± 
2384 
16603± 
3068 
20473± 
1823 
28213 
±1725 
23999 
±2094 
15420± 
2264 
Atorvastatin+RU486 
38851± 
2657 
38461± 
2602 
20352± 
2001 
19304± 
2987 
23947 
±2615 
23958 
±2055 
16514± 
1636 
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Fig5.03: All groups had significant reduction in infarct size when compared to methanol 
controls (p value <0.05). 
 
The mean infarct/AAR % for the various groups were as follows:(a) Vehicle 
(Methanol) control hearts was 47±4%, (b) RU486 treated hearts was 22.±3% (p 
value <0.001 when compared with control), (c) ATV treated hearts was 22±3% 
(p value <0.001 when compared with control) and  (d) ATV+RU486 treated 
hearts was 17±2% (p value < 0.001 when compared with control). 
From these results it is clear that the GCR blocker, RU486, when administered 
acutely during reperfusion is able to protect the ischaemic-reperfused 
myocardium. Infact it would seem to be more protective when administered with 
Atorvastatin although this did not approach significance. As this is the case we 
were unable to conclude from the infarct size analysis as to whether 
Atorvastatin acts via the GCR as the pharmacological agent used to block this 
receptor in itself is cardioprotective. 
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5.4 DISCUSSION 
These results clearly demonstrate that Atorvastatin is cardioprotective when 
administered at the onset of reperfusion. We were unable to conclude if this 
action was mediated via the GCR as the GCR antagonist was in itself 
cardioprotective. 
Statins have been suggested to have the same binding affinity towards the 
glucocorticoid receptor as steroids and Atorvastatin has the same degree of 
affinity as that of dexamethasone273. Corticosteroids also acutely protect the 
heart from reperfusion injury by activating Akt and phosphorylation of GSK- 
3β274. The glucocorticoid, dexamethasone has also been shown to increase the 
levels of Heat Shock Protein 72 (HSP 72) by inducing its transcription factor, 
HSF-1 (Heat Shock Factor-1), and thus protect adult rat cardiomyocytes from 
hypoxia-reoxygenation injury312. Atorvastatin has also been shown to 
phosphorylate HSP27 and thus attenuate reperfusion injury in a mouse ex vivo 
model261. In a mouse Langendorff model, dexamethasone has been shown to 
be cardioprotective and this was abrogated by the inhibition of COX-2 
(Cycloxygenase-2 thus indicating that the increase in the production of 
arachidonic acid metabolites was linked to the GCR313. Atorvastatin 
administered pre-ischaemically to rat hearts was shown to have an infarct 
sparing action that paralleled the activation of COX-2259. It would appear that 
statins and steroids are similar in their ability to acutely protect the myocardium 
and given the affinity of Atorvastatin to the GCR, it would seem reasonable to 
hypothesize that Atorvastatin-induced cardioprotection was in some way linked 
to the GCR. 
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There is conflicting evidence about the downstream effectors of 
dexamathasone when administered acutely during ischaemia-reperfusion. For 
example, Langendorff perfused rat hearts were shown to have a smaller infarct 
size when treated with dexamethasone prior to ischaemia but this protection did 
not reflect in an increase in phosphorylation of Akt or HSP72 but was possibly 
related to Erk1/2 activation314. Dexamethasone has been shown to increase 
infarct size in Langendorff perfused rat hearts when administered in the 
perfusate pre-ischaemically and this effect has been attenuated by the use of 
the mineralocorticoid receptor antagonist Spironolactone but not the GCR 
antagonist RU 486315. This would suggest that glucocorticoid mediated 
cardioprotection may not be related to its action on the GCR and also may not 
be mediated via PI3K/Akt. 
There is also evidence to suggest that statins may well antagonize the effects of 
glucocorticoids and vice versa. Lovastatin has been shown to inhibit the 
prenylation of the G protein subunits which would thus be able to suppress the 
transcriptional actions of the GCR316. The isoprenoid intermediate, farnesyl 
pyrophosphate (which is a metabolite of mevalonic acid of the cholesterol 
biosynthetic pathway), has been shown to act via the GCR and inhibit 
epithelialisation and thus wound healing. Mevastatin by virtue of inhibiting 
mevalonate formation, reduces the levels of farnesyl pyrophosphate and thus 
indirectly inhibits GCR associated activity317. Fluvastatin has been shown to 
induce apoptosis in vascular endothelial cells by inhibiting the prenylation of ras 
Signal transduction pathway (required for cell survival) and this effect has been 
reversed by the use of dexamethasone via its interaction with GCR although 
this inhibition is not specifically targeted at Fluvastatin activity318. 
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Thus despite the simple elegance of our hypothesis, it would seem that the 
interaction between steroids, statins and GCR activity is quite complex. While 
there is evidence to suggest that corticosteroid and statins have similar action in 
protecting the myocardium against the effects of reperfusion injury, there is also 
evidence that steroids and statins may antagonize each other’s effects and also 
that the mechanism of action of steroid induced cardioprotection may well be 
via the mineralocorticoid receptor activation as against GCR activation. 
These experiments reveal that ethanol used as a solvent for RU486, was 
protective when administered during reperfusion. There is ample evidence to 
suggest that acute ethanol administration prior to ischaemia acts via a Protein 
Kinase C- δ (PKC-δ) which then activates PKC-ε which is known to be 
cardioprotective by inhibition of the MPTP. However this is dependent on the 
timing of ethanol administration prior to ischaemia, as sufficient time must 
elapse for the PKC to translocate to the mitochondria319. It would thus appear 
that this is unlikely to be the mechanism of ethanol induced cardioprotection, 
demonstrated in these experiments. Ethanol has various potential targets such 
as adenosine receptors, opioid receptors, free radicals etc320, all of which have 
been shown to be involved in cardioprotection. It is well known that some of the 
targets of preconditioning and postconditioning are the same and  this may well 
be one of the reasons that ethanol administered at the onset of reperfusion 
reduced the infarct size. 
In the above mentioned experiments, RU486 was seen to be protective in the 
setting of myocardial ischaemia-reperfusion. This may be due to the following 
reasons: (a) The partial agonist activity of RU486. This partial agonist activity of 
RU486 is dependent on the GCR levels321 and also the N-terminus portion of 
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the GCR322. In the presence of high levels of GCR, RU486 acts as an agonist. 
In the experiments discussed in this thesis, exogenous glucocorticoids were not 
administered. Thus there might have been significant availability of GCR for the 
RU486 to bind to, resulting in an agonist activity, (b) The cardioprotection may 
also be as a result of the inhibition of chronic cortisol associated infarct 
expansion323, (c)  The amino acids glutamate and aspartate are released by 
cardiomocytes during ischaemia324 and glutamate has been shown to be 
cardiotoxic in H9C2 myocytes. RU486 pre-treatment is said to reduce this 
cardiotoxic effect and may well be a potential mechanism of RU486 induced 
cardioprotection325, and (d) RU486 has also been shown to posses antioxidant 
properties that may well mop up the harmful ROS326 (Reactive Oxygen 
Species). 
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5.5 CONCLUSION 
The data presented demonstrates that Atorvastatin when administered acutely 
during reperfusion reduces infarct size expansion due to reperfusion injury in 
isolated Langendorff perfused rat hearts. However the GCR antagonist, RU486, 
was in itself cardioprotective and thus it was not possible to conclude as to 
whether Atorvastatin induced cardioprotection was associated with GCR 
activation. These experiments could not be repeated with an alternative GCR 
blocker as the only other antagonist is currently unavailable. However these 
experiments could be potentially performed in a different model such as a 
mouse ‘knock-out’ model in which the GCR responsive elements are inactive327. 
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6. ESTABLISHING THE ROLE OF ADENOSINE IN ATORVASTATIN 
MEDIATED PROTECTION AGAINST REPERFUSION INJURY 
6.1 AIMS AND HYPOTHESIS 
Adenosine is a well known cardioprotective agent and has been implicated in 
ischaemiac preconditioning328-331. There is also evidence to suggest that statin 
mediated cardioprotection involves adenosine, when statins have been 
administered prior to ischaemia246-230,332-334. We hypothesized that Atorvastatin 
administered during reperfusion, mediated its cardioprotection by involving 
adenosine and that this effect could be blocked by the adenosine receptor 
antagonist, 8-sulpho phenyl theophylline (SPT). We tested this using a 
Langendorff rat heart model to assess infarct size following ischaemia and 
reperfusion in the presence of atorvastatin administered prior to ischaemia and 
at reperfusion. 
6.2 METHODS 
Langendorff perfused rat hearts were used and the various groups were 
subjected to 35 minutes of ischaemia and 120 minutes of reperfusion as 
discussed in chapter 3. 51 hearts were used of which 5 were excluded as they 
did not attain acceptable baseline parameters during stabilization, 5 hearts were 
excluded due to precipitation of Atorvastatin in the rig and a further 10 were 
excluded due to small AAR or small infarct size, which did not meet the 
predefined inclusion criteria. Results were expressed as Infarct size/AAR ± 
SEM % and the results were tested for significance with one way Anova test 
followed by Tukey’s  test (p value <0.05). 
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The hearts were divided into the following 4 groups. In each case the drugs or 
vehicle were administered for the last 5 minutes of ischaemia and the first 15 
minutes of reperfusion only (see Figure 6.01): 
(a) Controls: Perfused with methanol (0.1%).  
(b) Atorvastatin: Hearts perfused with atorvastatin at a dose of 50 µmol/l. 
(c) SPT: Hearts were perfused with the non specific adenosine receptor 
antagonist, 8- Sulfophenyl theophylline (SPT), during reperfusion. This was 
used at a dose of 100 µmol/L and it was dissolved in the buffer directly. SPT 
has been used at various doses ranging from 10 µmol/L to 100 µmol/L. 
However a dose of 100 µmol/l has been shown to antagonize the effect of 
adenosine receptors in isolated perfused rat hearts335,336. 
(d) A combination of ATV and SPT at a dose of 50 µmol/l and 100 µmol/l 
respectively. SPT was perfused for 2 minutes before the combination of the 
ATV and SPT. This was so as to allow the SPT to reach and inhibit the 
adenosine receptors prior to the introduction of ATV. 
Protocol 
    
 
   
 
       0                                            40                         70             90                                                       195 Minutes 
   Fig6.01: Protocol: Drug: ATV, SPT, ATV+SPT. Vehicle: Methanol (Control) 
 
 
 
 
 
 
Drug/ 
Vehicl
e (20 
min) 
Stabilization (40 min) Ischaemia (30 
min) 
Reperfusion (105 min) 
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6.3 RESULTS 
6.3.1 ATORVASTATIN AND SPT AT REPERFUSION 
The baseline parameters for all hearts were similar except in the case of the 
hearts perfused with the combination of ATV and SPT, in which the developed 
pressure and RPP were significantly higher when compared to the methanol 
(control) group. Again as all drug therapy was at the onset of reperfusion, this 
difference is not related to drug therapy (tables 6.01,6.02 and 6.03 and figure 
6.02). 
Baseline Characteristics 
 
Groups Number Body Weight (gms±SEM) 
Methanol (Control) 7 464±13 
Atorvastatin (ATV) 9 433±17 
SPT 7 410±27 
ATV+SPT 8 408±27 
Table 6.01: Body weight (gms ± SEM). 
 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol(Control) 16±1 15±1 8±0.4 7±0.5 14±0.5 12±1 6±0.7 
ATV 16±1 15±0.5 7±0.2 7±0.4 15±0.6 12±1 6±0.7 
SPT 17±1 16±1 6±0.3 6±0.3 14±0.6 12±1 7±1 
ATV+SPT 16±1 15±1 6±0.5 6±0.4 12±1 11±1 6±0.6 
Table 6.02: Coronary flow rate (ml/min). S-stabilization, I-Ischaemia & R-Reperfusion. 
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Table 6.03: Rate pressure product. S-stabilization, I-Ischaemia & R-Reperfusion. 
 
Figure 6.02: Infarct/AAR for ATV+SPT administered at reperfusion. **p<0.05 when    
compared to control.  
The Infarct/AAR in the four groups was as follows: control- 42±5%, SPT-31±4, 
ATV- 23±3 (P <0.01 when compared with control) & ATV+SPT- 22±2 (p value 
<0.01 when compared with control). The ATV and ATV+SPT group had 
significantly lower infarct sizes when compared to controls (p value <0.01). 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol 
(Control) 
31234±
4773 
27795±
2311 
13356±
1757 
19649±
2021 
26797±
2255 
24667±
2872 
14704±
2890 
ATV 
36237±
3757 
34335±
2128 
16594±
2090 
20693±
3188 
27403±
1915 
26871±
1759 
15295±
2383 
SPT 
37791±
3879 
35502±
3227 
16162±
2196 
18326±
1927 
28293±
1248 
27446±
2216 
19471±
1558 
ATV+SPT 
46191±
3648* 
46191±
3648* 
17185±
2628 
23449±
1515 
25977±
1170 
28503±
2810 
20464±
1967 
                      
Methanol (Control)             8-SPT                       ATV                      ATV+SPT 
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It is thus clear that the protection obtained by acute administration of 
Atorvastatin during reperfusion, is not abrogated by the non-selective 
adenosine receptor antagonist 8-SPT. In order to explore the possibility of 
different mechanisms of Atorvastatin-induced acute cardiovascular protection in 
two different settings i.e, prior to ischaemia and at reperfusion, experiments 
were performed to measure infarct size in Langendorff perfused rat hearts when 
Atorvastatin was administered prior to ischaemia.  
6.3.2 ATORVASTATIN ADMINISTERED PRIOR TO ISCHAEMIA  
The hearts were again divided into four groups as follows: 
(a) Controls (Methanol): Perfused with methanol (0.1%). Following the first 10 
minutes of stabilization, methanol dissolved in buffer was perfused for 20 
minutes followed by a 10 minute wash out period, prior to ischaemia (Figure 
6.03: Protocol A). 
(b) Atorvastatin: Perfused with Atorvastatin at a dose of 50 µmol/L. The protocol 
was similar to that for the control hearts (Figure 6.03: Protocol A). 
(c) SPT: SPT dissolved in buffer was perfused at a dose of 100 µmol/L during 
the last 5 minutes of ischaemia and the first 15 minutes of reperfusion (Figure 
6.03: Protocol B). 
(d) Atorvastatin + SPT: In this protocol, Atorvastatin was perfused prior to 
ischaemia as mentioned above and SPT was perfused during reperfusion as 
mentioned above (Figure 6.03: Protocol C). 
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          0          10                    30        40                              75                                                       195 Minutes 
B.  
           
 
 
        0                                         40                            70              90                                                       195 Minutes 
 
 
C.  
       
          
   
        0           10                 30        40                           70             90                                                 195 Minutes 
Figure 6.03: Protocols for Atorvastatin administration prior to ischaemia.  
28 hearts were used of which 2 were excluded due to poor heart function during 
stabilization and 2 hearts were not analysed as there was no washout period 
between drug administration and ischaemia. There was no significant difference 
between the groups in baseline characteristics. (tables 6.04, 6.05 and 6.06). 
 
 
 
 
 
 
 
 
Methanol/
ATV 
Ischaemia Reperfusion 
ATV Ischaemia S
P
T 
Reperfusion 
SPT 
(20 
minut
es) 
Stabilization (40 min) Ischaemia (30 
min) 
Reperfusion (105 min) 
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Baseline Characteristics 
Groups Number Body Weight (gms±SEM) 
Methanol (Control) 5 364±24 
Atorvastatin (ATV) 5 364±22 
SPT 6 365±23 
ATV+SPT 6 408±9 
Table 6.04: Mean Body Weight (gms ± SEM). 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol(Control) 19±0.7 17±0.8 7±0.5 7±0.5 14±0.5 13±0.5 8±0.9 
ATV 18±1 18±0.5 7±0.9 7±0.9 14±0.9 13±0.4 8±0.8 
SPT 17±0.7 16±0.8 8±0.5 8±0.6 13±0.3 12±0.7 8±0.9 
ATV+SPT 20±0.7 19±1 7±0.8 7±0.9 14±1 12±1 8±0.8 
Table 6.05: Mean Coronary flow rate (ml/min ± SEM). S-stabilization, I-Ischaemia & R-
Reperfusion. 
 
 
Table 6.06: Mean Rate Pressure Product. S-stabilization, I-Ischaemia & R-Reperfusion. 
 
 
 
 
 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol 
(Control) 
50136±
2657 
45106±
1846 
24976±
1757 
27328±
2390 
32306±
1191 
34670±
1731 
26935±
909 
ATV 
45948±
3456 
47154±
2857 
19006±
2090 
26697±
2872 
32682±
2333 
33965±
1864 
28304±
1757 
SPT 
45059±
5947 
43016±
4943 
23250±
2196 
29722±
4505 
33308±
2624 
33235±
2070 
23762±
2414 
ATV+SPT 
48012±
4270 
41105±
5998 
20405±
2628 
26473±
4978 
34098±
4828 
33702±
5502 
26031±
3903 
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Methanol (Control)              ATV                          SPT                        ATV+SPT 
 
Figure 6.04: Infarct/AAR % with pre-ischaemic administration of ATV. ** p value <0.05 
when compared with control. 
The mean infarct sizes as a percentage of the AAR ± SEM for the various 
groups were as follows:(a) Control: 43±6% (b) SPT: 46±3% (c) ATV: 25±1% (p 
value <0.05 when compared with control) (d) ATV+SPT: 42±3% (p value <0.05 
when compared with ATV). It is thus clear that Atorvastatin is cardioprotective 
even when administered acutely prior to ischaemia and this protection is 
blocked by the adenosine receptor antagonist, SPT. 
6.4 DISCUSSION 
These experiments thus demonstrate that Atorvastatin is cardioprotective when 
administered prior to ischaemia and at the onset of reperfusion. However SPT 
is able to abrogate the protection of pre-ischaemic administration of Atorvastatin 
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thus demonstrating the role of adenosine at reperfusion but is unable to 
abrogate the protection associated with administration of Atorvastatin at the 
onset of reperfusion. 
Adenosine is a purine nucleoside which is widely distributed in tissues and 
plays a central role in the energy metabolism of the cell337. Its formation is 
closely related to the energy consumption of the cell337. High levels of 
adenosine accumulate in the extra cellular space during ischaemia/hypoxia and 
its levels gradually subside during reperfusion338. It is produced by the action of 
5’ nucleotidase which dephosphorylates Adenosine Mono Phosphate (AMP) 
and the hydrolysis of S-Adenosyl homocysteine339 (Figure 6.05).  
 
Figure 6.05: Adenosine is produced by the action of ecto 5’nucleotidase on adenosine 
mono phosphate (AMP) and the action of S-adenosyl homocysteine hydrolase (SAH-
hydrolase) on SAH. Adenosine is degraded to inosine by adenosine deaminase which is 
subsequently converted to hypoxanthine. IMP-Inosine Mono Phosphate, ITU: 
iodotubericidine, blocks adenosine kinase and thus inhbits the conversion of adenosine 
to AMP, NBTI: n-nitorbenzyl thioinosine, blocks adenosine membrane transport, EHNA: 
erythro-6 (2- hydorxy-3-nonyl)-adenine, blocks adenosine deaminase and thus inhibits 
the degradation of adenosine. Taken from Frobert et al340.  
 131 
There are numerous studies to show that adenosine is cardioprotective and 
these have been discussed in detail in two excellent reviews178,341. I will discuss 
a few relevant examples as follows. Adenosine has been shown to reduce 
infarct size when administered to isolated perfused rabbit hearts, prior to 
ischaemia and this mirrored the protection obtained by the preconditioning 
protocol331. In the same group of experiments, the non-specific adenosine 
receptor antagonist was shown to abrogate the infarct size limitation of 
preconditioning331. Further confirming the role of adenosine, in isolated 
perfused rat hearts, a preconditioning cycle increased the amount of adenosine 
measured by microdialysis329. It was subsequently demonstrated that Ischaemic 
Preconditioning (IPC) was mediated through A2B adenosine receptors and was 
dependent on an increase in ecto5’nucleotidase activity (responsible for 
production of adenosine), in a transgenic A2B receptor deficient mouse 
model328. In Langendorff perfused rabbit hearts it was demonstrated that 
ischaemic preconditioning (and thus adenosine) activated Protein Kinase C 
(PKC) which interacted with adenosine A2B receptors during reperfusion and 
stimulated Akt/Erk1/2 components of the RISK pathway330. 
As already discussed in section 1.4.1, statins administered preischaemically in 
a dog invivo model reduced infarct size and this was mediated by activation of 
ecto5’nucleotidase after the first 15 minutes of reperfusion, which in turn was 
associated with Akt activation247. As mentioned previously, recently it has been 
demonstrated by Western blots in rat hearts that statin activation of ERK1/2 is 
dependent on PI3 Kinase induced increase in ecto5’nucletidase which then 
increases extracellular levels of adenosine resulting in interaction with the 
adenosine receptors (including A2b)248. Pravastatin administered to rabbit 
hearts prior to ischaemia has been shown to have a PKC dependent, infarct 
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sparing action332. In human endothelial cells Atorvastatin was shown to 
accelerate the degradation of nucleotides and increase the production of 
adenosine and this was shown to be associated with an increase in the activity 
of ecto5’nucleotidase334. As already discussed Pravastatin has been shown to 
have some interaction with adenosine metabolism when administered to 
patients prior to angioplasty246. In a double blind study with 21 human 
volunteers, Rosuvastatin administered prior to induction of forearm ischaemia 
demonstrated an improved vasodilator effect to dypiridamole (decreases 
endocytotic turnover of adenosine and thus increases extracellular adenosine) 
and this effect was abolished by the adenosine antagonist caffeine333. This 
study showed some indirect evidence that the augmentation in the level of 
endogenous adenosine was probably due to the effect of Rosuvastatin on 
ecto5’nucleotidase. 
Adenosine production in the interstitial compartment increases under conditions 
of stress such as ischaemia and these levels gradually normalize with reflow338. 
The extracellular adenosine is recycled to form AMP by adenosine kinase, 
when a sufficient concentration gradient has been established and under well 
oxygenated condition342. However the low pH and hypoxia associated with 
ischaemia results in inhibition of adenosine kinase and an increase in the 
extracellular levels of adenosine. The extracellular production of adenosine 
under conditions of hypoxia is linked to the activity of ecto5’nucleotidase. 
Indeed in experiments with vascular endothelial cells, hypoxia has been shown 
to increase the cell surface expression of ecto5’nucleotidase over time and also 
increase its availability on the cell surface by reducing the endocytotic 
turnover343. This increase in the activity of ecto5’nucleotidase and thus 
availability of adenosine does not necessarily translate into cardioprotection and 
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an additional stimulus such as preconditioning331, adenosine infusion (pre-
ischaemia)329 or postconditioning344 is required to enhance the affinity of 
adenosine to its receptor targets. 
Adenosine acts via the A1 , A2A, A2B and A3 receptor subtypes. The binding of 
adenosine to A1 and A3 receptors reduces c-AMP levels while  its binding to 
A2A & A2B receptors enhances adenylyl cyclase activity and thus increase the 
production of intracellular c-AMP340. A1 and A3 receptors increase the levels of 
PKC340 (figure 6.06). Adenosine induced cardioprotection due to 
preconditioning was shown to be mediated by A1 receptors in in vivo rabbit 
hearts345.  In a transgenic mouse knock out model it was demonstrated that the 
preconditioning effect was mediated via ecto5’nucleotidase and A2B 
receptors328.  
 
Figure 6.06: Adenosine receptors and effectors. +: Activates Adenylate cyclase and -: 
Inhibits Adenylate cyclase. Adapted from Aderis pharmaceuticals. 
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The role of adenosine in the reperfusion phase is unclear with conflicting 
evidence. Intravenous adenosine and receptor agonists have been shown to be 
protective when given acutely during reperfusion in a rabbit invivo model and a 
dog invivo model346,347. On the other hand in the same species with similar in 
vivo models, adenosine administered at reperfusion has not been shown to be 
protective348,349. The AART trial in rabbits with A1 receptor agonist administered 
in vivo at reperfusion did not demonstrate any cardioprotection350. The clinical 
trials AMISTAD 1 & 2 did demonstrate some reduction in infarct size in specific 
patient sub-groups but did not offer any prognostic benefit180,181. AMISTAD was 
a prospective, open-label trial of thrombolysis with randomization of 236 
patients to adenosine or placebo within 6 hours post infarction. The primary end 
point was infarct size reduction measured by Tc-99 sestamibi SPECT scan 5-7 
days post infarction and secondary end point was myocardial salvage index and 
composite of in-hospital outcomes. Patients with an anterior infarct who 
received adenosine had a 67% relative reduction in infarct size and were more 
likely to reach the composite clinical outcomes. AMISTAD-2 trial was a 
randomized multicentre double-blinded placebo-controlled trial of adenosine as 
an adjunct for reperfusion in the treatment of acute myocardial infarction. 2118 
patients were recruited and infarct size was measured in 236 patients with Tc-
99 sestamibi SPECT. The pooled adenosien group had a smaller infarct size 
and this positively correlated with fewer clinical outcomes. 
 Given the evidence it would appear that adenosine induced cardioprotection is 
dependent on pre-ischaemic augmentation of adenosine levels which in turn 
increases the activity of PKC and also increases the levels of ectonucleotidase, 
resulting in A2B mediated activation of the RISK pathway at reperfusion. 
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A2B receptors however have low affinity for adenosine. PKC activation in the 
first few minutes of reperfusion has been shown to be essential for 
cardioprotection by preconditioning (and thus adenosine mediated 
cardioprotection)351. Preconditioning would increase the levels of PKC which 
would then increase the affinity of the A2B receptor for endogenous adenosine 
and thus trigger cardioprotection through the RISK pathway339. Initial increase 
in PKC activity is dependent on adenosine A1 and A3 receptors which couple 
directly with PKC via phopholipase activation352. Thus the implication is that any 
agent (in this case Atorvastatin) that were to mimic preconditioning induced 
enhanced sensitivity of adenosine to the A2B receptor, will have to be 
administered sufficiently early for the PKC activation to take place (figure 6.07). 
 
Figure 6.07: Adenosine and cardioprotection. Adenosine acts via the A1 and A3 
receptors to increase the levels of Protein Kinase C (PKC) during ischaemia and this in 
turn enhances the sensitivity of A2B receptors to adenosine which subsequenly 
activates the RISK pathway. Adapted from Cohen et al339. 
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As previously discussed statins enhance the levels of ecto5’nucleotidase, 
adenosine levels and PKC activity when administered prior to ischaemia. This 
effect may well mimic the preconditioning induced PKC dependent 
cardioprotection. This would also imply that statins need to be administered 
sufficiently prior to ischaemia to activate PKC and enhance the affinity of the 
A2B receptors to adenosine which in turn activate the RISK pathway. However 
as discussed in previous sections, the experiments in dog in vivo model do 
show that ecto5’nucleotidase levels rise only after 15 minutes of reperfusion 
and that this is important for the cardioprotection even of statins, administered 
prior to ischaemia in these experiments247. This is the only experimental 
evidence to suggest that in addition to its activity during ischaemia, 
ectonucleotidase activity is maintained in reperfusion. In the same group of 
expriments, the activation of ecto5’nucleotidase was dependent on PI3 Kinase 
activation which occurs during the first few minutes of reperfusion. It could thus 
be argued that pre-ischaemic delivery of statins increase the activity of PKC 
during ischaemia and this primes the A2b receptors to the effects of adenosine 
which in turn is responsible for the activation of PI3 kinase and 
ecto5’nucleotidase during reperfusion. This further increases the levels of 
adenosine which in turn activates the RISK pathway.  
In the current study, SPT was shown to abrogate the infarct size reduction of 
pre-ischaemic delivery of Atorvastatin while it did not have any effect on the 
infarct size reduction of Atorvastatin administered at reperfusion. This may be 
due to the following reasons: 
(a) Pre-ischaemic Atorvastatin possibly activates ectonucleotidase and PKC 
which in turn enhances the affinity of the A2B receptors for endogenous 
adenosine but Atorvastatin administered during reperfusion has skipped the 
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PKC activation mediator phase (and thus the A2B activation) and is thus unable 
to directly interact with the adenosine receptor. This is backed by previous work 
which has demonstrated that adenosine or its agonists are ineffective when 
administered during reperfusion345,348-350,353-355. This also brings to fore the fact 
that there are probably multiple mechanisms by which statins are 
cardioprotective. 
(b) It may be due to species difference. Ecto5’nucleotidase is abundant in rat 
cardiomyocytes but not so in the arterial myocytes356. The concentration of 5’-
nucleotidase in the pericytes of endothelium is higher in dogs and guinea pigs 
when compared to rats357. However dog myocardium was not reactive to 
5’nucleotidase. This difference in the relative concentration of the enzyme 
between different compartments of the same tissue type and also between 
different species may contribute to differences in adenosine metabolism. 
(c) In addition, in my studies, Atorvastatin was perfused for a period of only 20 
minutes , 15 minutes of which were in the reperfusion phase. This maybe the 
reason, that we did not observe the benefit of delayed ectonucleotidase 
activation that has been reported in dogs wherein the enzyme is activated only 
after 15 minutes of reperfusion247. 
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6.5 CONCLUSION 
These results thus demonstrate that Atorvasatin is able to reduce infarct size 
when administered prior to ischaemia and during reperfusion. The protection 
seen with pre-ischaemic atorvastatin is lost when co-administered with SPT, 
suggesting involvement of adenosine metabolism. However this 
cardioprotection is not blocked by SPT when Atorvastatin is administered during 
reperfusion suggesting a non-adenosine dependent unrelated mechanism may 
be involved. 
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7. ATORVASTATIN, MEVALONIC ACID AND RHO A METABOLISM 
7.1 AIMS AND HYPOTHESIS 
Statins inhibit HMG CoA reductase, the rate limiting enzyme in the cholesterol 
biosynthetic pathway213. As already mentioned statins reduce infarct size when 
administered during reperfusion by activating the RISK pathway8. Statins also 
inhibit the prenylation of Rho A and thus inhibit the activation of Rho Kinase 
(ROCK)14. Rho A and ROCK are inhibitors of PI3K and eNOS14. We thus 
hypothesised that Atorvastain administered acutely during reperfusion protects 
the heart by inhibiting Rho A. In order to demonstrate this, mevalonic acid was 
used. Mevalonic acid is a precursor of cholesterol and isoprenoid synthesis and 
is the rate limiting step in the synthesis of isoprenoids. We used infarct size 
measurements and Western blotting for Rho A activation. 
7.2 METHODS 
Langendorff perfused Sprague –Dawley rat hearts were subjected to one of the 
following protocols: One set of experiments for infarct size analysis was carried 
out as per standard ischaemia–reperfusion protocol with 40 minutes of 
stabilization, 35 minutes of ischaemia and 120 minutes of reperfusion. In this 
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set of experiments vehicle and drugs were administered during the last five 
minutes of ischaemia and for the first 15 minutes of reperfusion. In the second 
set of experiments the Langendorff perfused hearts were subjected to 40 
minutes of stabilization, 35 minutes of ischaemia and 15 minutes of reperfusion 
with vehicle and drug perfused for the last 5 minutes of ischaemia and 15 
minutes of reperfusion. At the end of 15 minutes of reperfusion, the suture 
around the LAD was tied and a small quantity of Evan’s blue was injected to 
just about delineate the area at risk and the risk area was quickly excised and 
snap frozen in liquid nitrogen. The samples were then processed as per 
Western blot technique, which has been discussed in section 3. 
 For infarct size analysis the following groups were included:  
(a) Control (Vehicle): Methanol in Krebs buffer at a dose of 0.1 % was perfused 
during reperfusion as per protocol A in figure 7.01. 
(b) Atorvastatin: Atorvastatin dissolved in methanol and buffer was perfused at 
a dose of 50 µmol/l as per protocol A in figure 7.01. 
(c) Mevalonic acid: Mevalonolactone was purchased from Sigma–Aldrich 
chemicals. Mevalonolactone was converted to mevalonic acid by dissolving it in 
0.1 M sodium hydroxide and then heating it at 50 ºc for 2 hours. To this was 
added 0.1 M hydrochloric acid and the pH was adjusted to 7.4358. Mevalonic 
acid was used at a dose of 1 mmol/l. This dose has been shown to inhibit the 
effect of statins on NO activity in porcine arterioles359. Mevalonic acid dissolved 
in buffer was perfused as per protocol A in figure 7.01. 
(d) Atorvastatin + Mevalonic Acid: The combination of drugs were dissolved in 
buffer and perfused as per protocol A in figure 7.01. 
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Infarct size analysis was carried out as described before. Results were 
expressed as Mean Infarct/AAR % ±SEM and tests of significance were carried 
out with one way ANOVA testing and tukey post test comparison using 
Graphpad Prism software (version 5.0) with a p value of <0.05 considered 
significant. 
The following groups were used for Western blot analysis: 
(a) Control (Vehicle): Methanol in Krebs buffer at a dose of 0.1 % was perfused 
during reperfusion as per protocol B in figure 7.01. 
(b) Atorvastatin: Atorvastatin dissolved in methanol and buffer was perfused at 
a dose of 50 µmol/l as per protocol B in figure 7.01. 
(c) Mevalonic acid: Mevalonic acid was dissolved in buffer at a dose of 1 mmol/l 
and perfused as per protocol B in figure 7.01. 
(d) Atorvastatin + Mevalonic Acid: The combination of drugs were dissolved in 
buffer and perfused as per protocol B in figure 7.01. 
The samples were then processed as per the protocol for Western blot analysis 
and the relative density of the bands was measures and test of significance was 
carried out using one way ANOVA with a p value of <0.05 considered 
significant. 
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Protocol A: 
     
 
   
 
       0                                            40                         70             90                                                       195 Minutes 
Drug: Atorvastatin, Mevalonic acid, ATV+ Mevalonic acid 
Vehicle: Methanol 
Protocol B 
 
 
   
        0                                            40                        70                                      90 minutes (Snap freeze)       
      Drug: Atorvastatin, Mevalonic acid, ATV+ Mevalonic acid 
      Vehicle: Methanol 
Figure 7.01: Experiment protocols. 
7.3 RESULTS 
7.3.1 REPERFUSION SALVAGE- IINFARCT SIZE 
36 Sprague –Dawley rats were used for this set of experiments. 5 hearts were 
excluded due to technical reasons and 5 were excluded due to criteria 
explained in previous sections. 
Baseline Characteristics:  
Group Number Body Weight. 
Control 8 432±23 
ATV 6 421±14 
Mevalonic Acid 6 447±29 
ATV+ Mevalonic acid 6 438±13 
Table 7.01: Mean Body Weight (gms± SEM) 
 
 
 
Drug/ 
Vehicl
e (20 
min) 
Stabilization (40 min) Ischaemia (30 
min) 
Reperfusion (105 min) 
Drug/ Vehicle (20 min) - 
Last 5 minutes of 
ischaemia and 15 minutes 
of reperfusion 
Stabilization (40 min) Ischaemia (30 
min) 
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Group S10 S30 I5 I30 R5 R30 R120 
Methanol 
(Control) 
16 ± 
0.9 
15 
±0.7 7± 0.3 7 ± 0.4 14±0.4 12 ±1 7 ± 0.7 
ATV 17±1 
15 
±0.5 6 ±0.4 6 ± 0.4 16 ± 1 11±0.9 6± 1 
Mevalonic Acid 
18 ± 
0.6 17 ± 1 8± 0.6 8 ± 0.6 15 ± 1 12±0.9 7± 0.9 
ATV+Mevalonic 
Acid 17 ± 1 15 ± 1 6 ±0.8 6 ± 0.6 17 ± 1 12 ± 1 8 ± 0.9 
Table 7.02: Mean Coronary Flow Rate (ml/min ± SEM). S-Stabilization, I –Ischaemia, R-
Reperfusion. 
 
Groups S10 S30 I5 I30 R5 R30 R120 
Methanol 
(Control) 
33501± 
4592 
30334±
3237 
14395±
1837 
20710±
1927 
26818±
2214 
25548±
2693 
16249±
3134 
ATV 
40328± 
2787 
35526±
1698 
16281±
1917 
20801±
2170 
26305±
2101 
25886±
1580 
17629±
932 
Mevalonic 
acid(MEV) 
38881± 
3745 
35290±
3039 
19653±
2910 
23949±
2430 
26616±
2454 
26784±
2520 
20193±
3298 
ATV+MEV 
42873± 
4536 
38718±
4186 
16235±
3314 
23656±
3601 
23991±
3497 
29295±
3750 
23009±
2613 
Table 7.03: Mean Rate Pressure Product. S-Stabilization, I –Ischaemia, R-Reperfusion. 
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Infarct Size 
 
                      
 
Methanol (Control)        ATV                    Mevalonate              ATV+ Mevalonate 
 
  
Fig 7.02: Hearts treated with Atorvastatin were significantly protected when compared to 
vehicle control (p value <0.05) and this protection was abolished by the co-
administartion of mevalonic acid ( p value < 0.05 when compared with ATV) . 
The mean infarct size ± SEM for the groups were as follows: Control 40 ± 5%, 
Atorvastatin 19 ± 2% (p <0.05 when compared with control), Mevalonic acid 36 
± 4% and Atorvastatin + Mevalonic acid 40 ± 6% (p <0.05 when compared with 
ATV). The co-administration of Mevalonic acid abrogated the cardioprotective 
effect of Atorvastatin. 
7.3.2 REPERFUSION SALVAGE: WESTERN BLOTS 
Blots were performed for which 24 Spargue-Dawley rats were used. 3 hearts 
were not included as there was a problem with the Langendorff apparatus. 
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Results were expressed as a ratio of active RhoA to total Rho A and the total 
Rho A was normalized with β-actin (Figure 7.03 and 7.04). 
Western Blot Scans: 
(a) Active RhoA Blots (After processing for Active Rho-A): 
 
 (b) Total RhoA Blots: 
 
 
(c) Beta-actin Blots: 
 
Figure 7.03: Scanned Images of Western Blots. 
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Fig 7.04: Western blot results for Rho A. Total RhoA-N: Total rhoA-normalized. * p value 
<0.05 when compared to ATV and <0.01 when compared to MEV. 
These results demonstrate that Atorvastatin treated hearts have a reduced level 
of active rhoA and mevalonic acid treated hearts have a higher level of active 
rhoA but hearts treated with the combination of Atorvastatin and mevalonic acid 
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did not show a higher level of activated rhoA. However none of these results 
were statistically significant. 
7.4 DISCUSSION 
Statins inhibit HMG-CoA reductase, the rate limiting enzyme in the cholesterol 
biosynthetic pathway213. This enzyme catalyzes the conversion of HMG-CoA to 
mevalonic acid360. Mevalonic acid is the common precursor to both cholesterol 
and the isoprenoids. These isoprenoids include farnesylpyrophosphate and 
geranylgeranyl pyrophosphate213. These serve as important lipid attachments 
for the post translational modification of various proteins including Rho361. Small 
G proteins of the Rho family comprises 20 members in mammals362. Rho 
proteins regulate many cellular processes such as cytoskeletal and cell 
adhesion, cell polarity, endocytosis, vesicle trafficking, progression through the 
cell cycle, cell differentiation, oncogenesis and gene transcription363 . These 
Rho proteins act as a molecular switch and switch between an active GTP 
bound form and an inactive GDP bound form364 ( Figure 7.05).  
 
Figure 7.05: The Rho proteins alternate between an active GTP bound state and an 
inactive GDP bound state. The GEF (Guanine nucleotidide exchange factor) mediates 
nucleotidide exchange and thus activation. GAP (GTPase Activation Protein) catalyze 
hydrolysis of the GTPase and thus inactivation. The GDI  (Guanine nucleotidide 
exchange inhibitors) removes the inactive Rho protein from the membrane. Prenylation 
is essential for the translocation of the protein to the cell membrane. Taken from Etienne-
Manneville et al363. 
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All Rho proteins are prenylated at their carboxy terminus and this require the 
isoprenoid intermediates365. These prenylated proteins then translocate to the 
cell membrane in the GTP bound state and activate their effectors. The Rho 
proteins Rho A, Cdc 42 and rac proteins are the best characterized and of 
these the Rho A protein and its downstream effectors are the focus of 
cardiovascular protection364.  The Rho A protein, in addition to being prenylated 
and activated by binding to GTP, is also regulated by phosphorylation. 
Phosphorylation at the Serine 188 site by cAMP/cGMP dependent kinases 
(PKA and PKG) results in binding to GDI and thus extraction of the protein from 
membrane and inactivation366. 
The effectors of Rho A include the Rho associated coiled- coil Kinase (ROCK), 
Rhotekin, mDia-1 and PKN201. Of these ROCK is the most prominent and most 
well studied and has a role in myocardial reperfusion injury367. ROCK is a serine 
–threonine kinase that mediates many of the important downstream functions of 
Rho A256. ROCK consists of two isoforms: ROCK1 (ROKβ) and ROCK2 
(ROKα)368. ROCK1 is highly expressed in kidney, liver, spleen, lung and testis 
while ROCK2 is preferentially expressed in cardiac and brain tissue368. 
More than 15 substrates have been identified for ROCK201. ROCK targets the 
myosin phosphatase in vascular smooth muscles and thus results in calcium 
sensitization and vascular smooth muscle cell contraction369. It also 
phosphorylates troponin in cardiomyocytes and increases the tension 
generated during contraction370. Phosphatase and tensin homologue (PTEN) is 
a target of ROCK371. PTEN is a phosphatase that dephosphorylates both 
proteins and phosphoinositide substrates and has an important role in the 
regulation of intracellular signalling especially the PI3Kinase/Akt pathway 
(involved in the regulation of cell growth, cell survival and protein synthesis)201. 
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ROCK-associated phosphorylation of PTEN results in activation of the 
phosphatase activity of PTEN which subsequently results in the inhibition of the 
PI3kinase/Akt pathway201. Rho has been shown to activate PTEN in leukocytes 
and human embryonic kidney and the phosphatase action of PTEN has been 
shown to be dependent on the action of ROCK371. (Figure 7.06) 
Thus it would seem likely that the acute cardioprotection obtained by the 
administration could be due to its inhibition of RhoA prenylation which in turn 
would result in inhibition of ROCK and thus inhibition of the phosphatase activity 
of PTEN. This would eventually lead to activation of PI3K and eNOS. Indeed 
experiments in a Langendorff rat heart model has demonstrated an 
upregulation in PTEN phosphatase activity in chronic Atorvastatin treated 
hearts and this inhibitory action was overcome by an acute pre-ischaemic 
administration of Atorvastatin in a rat Langendorff model244. This partly formed 
the basis of my hypothesis.  
ROCK has also been shown to be responsible for reduced endothelial Nitric 
Oxide synthase (eNOS) activity during hypoxia in human endothelial cells by 
reducing stability of the eNOS mRNA and also reducing the  phosphorylation of 
eNOS254. This would suggest a more direct mechanism by which ROCK could 
inhibit components of the RISK pathway. ROCK has also been shown to inhibit 
phosphorylation of PI3kinase in vascular smooth muscle cells372. (figure 7.07). 
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Figure 7.06: ROCK, PTEN and NO:  ROCK possibly inhibits the action of PI3 kinase 
through PTEN. This in turn results in reduced eNOS phosphorylation, a reduction in NO 
and a subsequent reduction in Protein Kinase G (PKG), which eventually results in 
activation of the MPTP. Taken from Burley et al373. 
 
 
Figure 7.07: ROCK and NO: ROCK results in reduced stability of eNOS mRNA and 
reduced phosphorylation of eNOS. This is dependent on the activation of Rho A. Taken 
from Rikitake et al374. 
ROCK inhibition with Fasudil has been shown to attenuate infarct size in a rat 
in-vivo model when administered prior to ischaemia and this is associated with 
an increase in PI3 kinase and Akt activity256. Fasudil was also shown to reduce 
infarct size in a Langendorff perfused rat heart model when administered during 
reperfusion and this was due to an Akt/eNOS dependent mechanism203.  There 
is also evidence in diabetic in vivo and in vitro rat heart studies to suggest that 
acute inhibition of RhoA and ROCK is associated with increase contractile 
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activity375. Thus there is good evidence to suggest that acute inhibition of ROCK 
during reperfusion is cardioprotective. This would further lend support to the 
hypothesis that Atorvastatin-induced cardioprotection is likely to be due to 
RhoA/ROCK inhibition. 
In a rat in-vivo model, Rosuvastatin administered prior to ischaemia has been 
shown to reduce infarct size and this effect was abolished by the addition of 
geranylgeranyl pyrophosphate (GGPP) which overcomes the statin induced 
inhibition of rho A, and was also dependent on an increase in the cytosolic 
component of rho A257. It would thus appear that statin induced inhibition of rho 
A prenylation is central to its cardioprotective activity. It may also be central to 
PI3 Kinase/Akt activation in myocardial ischaemia –reperfusion injury. (figure 
7.08) 
 
Figure 7.08: Statins inhibit the prenylation of Rho A by a cholesterol independent 
mechanism. This results in a reduction in Rho A and ROCK which in turn results in 
activation of PI3Kinase/Akt and eNOS. Taken from Noma et al368. 
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The experiments described in this section of this thesis demonstrate that the 
infarct sparing action of Atorvastatin administered during reperfusion is 
abrogated by the administration of mevalonic acid (the common intermediate for 
both cholesterol and isoprenoids). However while the Western blots 
demonstrate a reduced level of active RhoA (negative regulator of PI3 kinase 
and eNOS) in the Atorvastatin treated group and an increase in activity in the 
mevalonic acid treated group, none of the values are significant. The Western 
blot results described in this section are statistically not significant possibly due 
to following two reasons. 
(a) The Rhotekin bead assay to measure active Rho A consists of an 
immunoprecipitation step which involves colourless slurry. During the multiple 
washing steps too little or too much of the sample may have been pipetted out 
to result in large standard errors and some false readings.  
(b) In addition the protein sample quantification was carried out in cardiac tissue 
that formed the ‘area at risk’. Thus if the tissue had a large amount of infarct 
there may have been very little viable tissue to give an accurate quantification 
of protein activation. This is especially true for the hearts treated with a 
combination of Atorvastatin & mevalonate which would have a higher infarct 
rate when compared to Atorvastatin treated hearts. This may be lent support by 
the fact that experiments in rats treated with Rosuvastatin were analysed for 
RhoA actvation in hearts that were not subjected to ischaemia-reperfusion239. 
Active RhoA is membrane bound and if tissue necrosis is quite large, active 
RhoA quantification may be difficult. This is purely conjecture and based on 
indirect evidence.  
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7.5 CONCLUSION: 
These experiments demonstrate for the first time that Atorvastatin-induced 
cardioprotection is due to its inhibition of HMG CoA reductase and that there is 
a suggestion that this maybe related to RhoA inhibition. 
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8. SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
8.1 SUMMARY OF FINDINGS 
The experiments in this thesis have demonstrated the following: 
(a) Atorvastatin is cardioprotective when acutely administered during 
reperfusion, in the in vitro rat heart model. This is the first time that this has 
been demonstrated in this model. As mentioned before the isolated rat heart 
model is a highly reproducible model that can be used to study biological, 
morphological and pharmacological indices in the absence of neuro-hormonal 
factors that are present in an in vivo model275. However the disadvantage of this 
model is that the extrapolation to intact human body may not always be 
relevant275. 
(b) The co-administration of RU486, the GCR blocker, to Atorvastatin treated 
hearts did not result in a loss of cardioprotection. However the GCR blocker in 
itself was cardioprotective and thus we were unable to conclude as to whether 
Atorvastatin acts via the glucocorticoid receptor. 
(c) Atorvastatin is cardioprotective when administered to rat heart (in vitro 
model) prior to ischaemia and at the onset of reperfusion. The protective effect 
of pre-ischaemic administration of Atorvastatin was abrogated by the non-
selective adenosine receptor antagonist, SPT, while co-administration at the 
onset of reperfusion did not have any effect. It could thus be concluded that 
Atorvastatin administered prior to ischaemia involves an adenosine dependent 
cardioprotective mechanism while when administered during reperfusion, it has 
an adenosine independent mechanism. 
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(d) Atorvastatin induced cardioprotection is abrogated by the administration of 
mevalonic acid. Western blot studies for RhoA activation revealed a reduction in 
active RhoA levels in Atorvastatin-treated hearts but this was not statistically 
significant. We have thus demonstrated for the first time that Atorvastatin 
induced cardioprotection in the in vitro rat heart model is due to its inhibition of 
HMG CoA reductase and that this maybe related to the inhibition of RhoA 
activation. 
8.2 CLINICAL APPLICATION 
Statin therapy is currently a part of standard therapy for primary and secondary 
prevention of Coronary Artery Disease. However it is largely used for its 
cholesterol beneficial effects and not necessarily at the higher dose necessary 
for its pleiotropic actions. The insights obtained from the work presented in this 
thesis will add to the scientific basis for the need to treat patients with acute 
coronary syndromes with appropriate doses of statins in order to be able to 
obtain the full infarct sparing effect of statins. 
This insight into mechanistic actions will also lead to the discovery of novel 
therapeutic agents that target the isoprenoid synthetic pathway and thus be 
used as an effective adjunct to conventional therapy in the setting of acute 
coronary syndromes. This will also rationalize the therapeutic approach in 
patients intolerant to higher doses of statins by either co-administration of rho 
kinase inhibitors or by offering a ‘one-off’ high dose statin regime during an 
acute coronary syndrome. 
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8.3 FUTURE DIRECTIONS 
Possible future research could be in the following spheres: 
(a) Laboratory research: 
•  The role of glucocorticoid receptor could be explored further by using 
mice knock-out models which lack the glucocorticoid response elements 
for the receptor. 
• The role of adenosine in the pre-ischaemic setting could also be 
explored by using specific adenosine receptor inhibitors and also the use 
of adenosine transport inhibitors. PKC activation and A2B sensitivity could 
be specifically explored in order to provide further insight into the 
mechanistic actions. 
• To demonstrate pleiotropy, cholesterol assays could be performed on the 
coronary effluent and also in the myocardium. If statin-induced 
cardioprotection were independent of cholesterol metabolism, the 
cholesterol levels in coronary effluent should essentially remain 
unchanged. RhoA activity assay could be carried out by alternative 
methods. 
• The experiments described here could be carried out in human atrial 
trabeculae model to demonstrate that these mechanisms may be relevant 
in humans. In this model, human atrial trabeculae harvested from patients 
undergoing CABG are suspended in buffer perfused organ baths and are 
paced. Contarctile activity is measured during simulated ischaemia and 
reperfusion and recovery of function is calculated. Ischaemia-reperfusion 
is simulated by alternating between hypoxic buffer and normoxic buffer. 
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Statins could be acutely perfused on the rig or given just prior to surgery to 
assess its effect on contractile activity. Better functional recovery would 
translate into cardioprotection376. 
(b) Clinical Research: 
• Clinical trials and proof of concept trials could be carried out in patients 
to assess the benefit of high dose statins in the setting of acute coronary 
syndromes, CABG and PCI. For this purpose troponin T or I could be used 
as a surrogate marker of myocardial injury or alternately ‘perfusion 
imaging’ using cardiac MRI could be used. 
• In CABG patients atrial trabeculae may be used to analyse the pattern of 
RhoA activation. 
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